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Abstract
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the EFSA was
requested to consider evaluations of ﬂavouring substances assessed since 2000 by the Joint FAO/WHO
Expert Committee on Food Additives (JECFA) and to decide whether further evaluation is necessary, as
laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a group of
22 pyridine, pyrrole and quinoline derivatives evaluated by JECFA (63rd meeting). The revision of this
consideration is made since additional genotoxicity data have become available for 6-methylquinoline
[FL-no: 14.042]. The genotoxicity data available rule out the concern with respect to genotoxicity and
accordingly the substance is evaluated through the Procedure. For all 22 substances [FL-no: 13.134,
14.001, 14.004, 14.007, 14.030, 14.038, 14.039, 14.041, 14.042, 14.045, 14.046, 14.047, 14.058,
14.059, 14.060, 14.061, 14.065, 14.066, 14.068, 14.071, 14.072 and 14.164] considered in this
Flavouring Group Evaluation (FGE), the Panel agrees with the JECFA conclusion, ‘No safety concern at
estimated levels of intake as ﬂavouring substances’ based on the Maximised Survey-derived Daily Intake
(MSDI) approach. Besides the safety assessment of these ﬂavouring substances, the speciﬁcations for
the materials of commerce have also been evaluated, and the information is considered adequate for all
the substances. For the following substances [FL-no: 13.134, 14.001, 14.030, 14.041, 14.042, 14.058,
14.072], the Industry has submitted use levels for normal and maximum use. For the remaining 15
substances, use levels are needed to calculate the modiﬁed Theoretical Added Maximum Daily Intakes
(mTAMDIs) in order to identify those ﬂavouring substances that need more reﬁned exposure
assessment and to ﬁnalise the evaluation.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
The substance 6-methylquinoline [FL-no: 14.042] is one of these substances. New genotoxicity data
on it was evaluated in the EFSA opinion FGE.77Rev1 (January 2014) but EFSA concluded that this new
data did not clear the concern with respect to genotoxicity in vitro and indicated that studies in vivo
would be necessary to address the potential for genotoxicity. EFSA evaluated FGE.77 again in January
2015 (FGE.77Rev2) due to new studies on other substances of this group, although at that time no
new data on FL-no: 14.042 was available.
On 27 January 2016 the Industry submitted a new dossier with the requested studies by EFSA.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information and, depending on the outcome, proceed to the full evaluation of this ﬂavouring
substance in accordance with Commission Regulation (EC) No 1565/2000.
2. Assessment
The approach used by EFSA for safety evaluation of ﬂavouring substances is referred to in
Commission Regulation (EC) No 1565/2000, hereafter named the ‘EFSA Procedure’. This Procedure is
based on the opinion of the Scientiﬁc Committee on Food (SCF) (SCF, 1999), which has been derived
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food Additives
(JECFA, 1995, 1996, 1997, 1999), hereafter named the ‘JECFA Procedure’. The Panel on Food Contact
Materials, Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA evaluation of
structurally related substances with the result of a corresponding EFSA evaluation, focussing on
speciﬁcations, intake estimations and toxicity data, especially genotoxicity data. The evaluations by
EFSA will conclude whether the ﬂavouring substances are of no safety concern at their estimated
levels of intake, whether additional data are required or whether certain substances should not be
evaluated through the EFSA Procedure.
The following issues are of special importance.
Intake
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI)
approach to estimate the per capita intakes of the ﬂavouring substances in Europe.
In its evaluation, JECFA includes intake estimates based on the MSDI approach derived from both
European and USA production ﬁgures. The higher of the two MSDI ﬁgures is used in the evaluation by
JECFA. It is noted that in several cases, only the MSDI ﬁgures from the USA were available, meaning
that certain ﬂavouring substances have been evaluated by JECFA only on the basis of these ﬁgures.
For Register substances for which this is the case the Panel will need European Union (EU) production
ﬁgures in order to ﬁnalise the evaluation.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
Flavouring group evaluation 77 revision 3
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2018;16(4):5226
When the Panel examined the information provided by the European Flavour Industry on the use
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would
grossly underestimate the intake by regular consumers of products ﬂavoured at the use level reported
by the Industry, especially in those cases where the annual production values were reported to be
small. In consequence, the Panel had reservations about the data on use and use levels provided and
the intake estimates obtained by the MSDI approach. It is noted that JECFA, at its 65th meeting
considered ‘how to improve the identiﬁcation and assessment of ﬂavouring agents, for which the MSDI
estimates may be substantially lower than the dietary exposures that would be estimated from the
anticipated average use levels in foods’ (JECFA, 2006b).
In the absence of more accurate information that would enable the Panel to make a more realistic
estimate of the intakes of the ﬂavouring substances, the Panel has decided also to perform an
estimate of the daily intakes per person using a modiﬁed Theoretical Added Maximum Daily Intake
(mTAMDI) approach based on the normal use levels reported by Industry.
As information on use levels for the ﬂavouring substances has not been requested by JECFA or has
not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the
mTAMDI approach for the substances evaluated by JECFA. The Panel will need information on use
levels in order to ﬁnalise the evaluation.
Threshold of 1.5 lg/person per day (Step B5) used by JECFA
JECFA uses the threshold of concern of 1.5 lg/person per day as part of the evaluation procedure:
‘The Committee noted that this value was based on a risk analysis of known carcinogens which
involved several conservative assumptions. The use of this value was supported by additional
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the
Committee, ﬂavouring substances for which insufﬁcient data are available for them to be evaluated
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 lg per person per
day would not be expected to present a safety concern. The Committee recommended that the
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended
to include the last step on the right-hand side of the original procedure (“Do the condition of use
result in an intake greater than 1.5 lg per day?”)’ (JECFA, 1999).
In line with the Opinion expressed by the SCF (SCF, 1999), the Panel does not make use of this
threshold of 1.5 lg/person per day.
Genotoxicity
As reﬂected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible
genotoxic potential of the ﬂavouring substances or of structurally related substances. Generally,
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro,
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. Substances
for which a genotoxic potential in vivo has been concluded, will not be evaluated through the Procedure.
Speciﬁcations
Regarding speciﬁcations, the evaluation by the Panel could lead to a different opinion than that of JECFA.
Structural relationship
In the consideration of the JECFA evaluated substances, the Panel will examine the structural
relationship and metabolism features of the substances within the ﬂavouring group and compare this
with the corresponding Flavouring Group Evaluation (FGE).
2.1. History of the evaluation of the substances in the present FGE
JECFA has evaluated a group of 22 ﬂavouring substances consisting of pyridine, pyrrole and
quinoline derivatives (JECFA, 2006a).
These 22 substances were considered by EFSA in FGE.77, in which the Panel concluded that
additional toxicity data were needed for seven substances [FL-no: 13.134, 14.001, 14.041, 14.045,
14.046, 14.047 and 14.068] as no adequate toxicity studies were available from which a no observed
adverse effect level (NOAEL) could be established, neither on the substances nor on supporting
substances. The Panel also concluded, contrary to JECFA, that 6-methylquinoline [FL-no: 14.042]
should not be evaluated through the Procedure due to concern with respect to genotoxicity in vitro.
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In the ﬁrst Revision of FGE.77, FGE.77Rev1, additional toxicity data were provided for isoquinoline
[FL-no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047]; the toxicity data on 2-
acetylpyrrole also cover 2-propionylpyrrole [FL-no: 14.068]. The main studies provided were for each
substance a 90-day study. Furthermore, additional genotoxicity data for 6-methylquinoline [FL-no:
14.042] became available. EU production volumes were provided for four substances, [FL-no: 14.045,
14.058, 14.059 and 14.164] for which the evaluation could not be ﬁnalised previously, due to lack of
these data. Based on these newly submitted EU production volumes (IOFI, 2013), the substances
were already evaluated in FGE.964 (EFSA CEF Panel, 2011), but for the sake of completion, the
information was included here as well. Finally, information on solubility was provided for six substances
[FL-no: 13.134, 14.007, 14.030, 14.038, 14.045 and 14.046] since the previous evaluation of FGE.77.
The second revision of FGE.77, FGE.77Rev2, included additional toxicity data, among which an oral
90-day study provided for 1-furfurylpyrrole [FL-no: 13.134]. The data were intended to cover the
re-evaluation of this substance as well as 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-
methylpyrrole [FL-no: 14.046]. A search in open literature was conducted for metabolism, genotoxicity
and toxicity for 1-furfurylpyrrole. This search did not reveal any pertinent new information on the
substance.
FGE
Opinion adopted
by EFSA
Link
No. of
candidate
substances
FGE.77 31 January 2008 http://www.efsa.europa.eu/en/efsajournal/pub/936.htm 22
FGE.77Rev1 19 February 2014 http://www.efsa.europa.eu/en/efsajournal/pub/3586.htm 22
FGE.77Rev2 19 December 2014 http://www.efsa.europa.eu/sites/default/files/scientific_
output/files/main_documents/3997.pdf
22
FGE.77Rev3 7 March 2018 https://www.efsa.europa.eu/it/efsajournal/pub/5226 22
The present revision of FGE.77, FGE.77Rev3, includes additional genotoxicity and toxicity data for
6-methylquinoline [FL-no: 14.042].
3. Presentation of the substances in the JECFA ﬂavouring group
3.1. Description
3.1.1. JECFA status
At the 63rd meeting, JECFA has evaluated a group of 22 ﬂavouring substances consisting of
pyridine, pyrrole and quinoline derivatives (JECFA, 2005b, 2006a).
3.1.2. EFSA considerations
The Panel concluded that all the substances in the JECFA ﬂavouring group of pyridine, pyrrole and
quinoline derivatives are structurally related to the group of pyridine, pyrrole, indole and quinoline
derivatives from chemical group 28 evaluated by EFSA in the Flavouring Group Evaluation 24, Revision
2 (FGE.24Rev2) (EFSA CEF Panel, 2013).
3.2. Isomers
None of the 22 ﬂavouring substances in the group of pyridine, pyrrole and quinoline derivatives has
possibility for stereoisomerism.
3.3. Speciﬁcations
3.3.1. Status
The JECFA speciﬁcations are available for all 22 substances (JECFA, 2005a) (see Table 1).
4 Consideration of 88 ﬂavouring substances considered by EFSA for which EU production volumes/anticipated production
volumes have been submitted on request by DG SANCO.
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3.3.2. EFSA considerations
The speciﬁcations are considered adequate for all 22 substances.
4. Assessment
4.1. Intake estimation
4.1.1. Status
For all 22 substances, evaluated through the JECFA Procedure, production volumes, based on which
MDSI values can be calculated, are available for the EU (see Table D.2).
4.1.2. EFSA considerations
For seven substances [FL-no: 13.134, 14.001, 14.030, 14.041, 14.042, 14.058, 14.072], the
Industry has submitted food categories5 and use levels in these for normal and maximum use (EFFA,
2012; DG SANCO, 2014) (see Table D.1, Appendix D). Based on the normal use levels, the mTAMDI
value can be calculated for each of these seven substances (see Table D.2, Appendix D). The mTAMDI
values for [FL-no: 14.041] is below the threshold of concern of 1,800 lg/person per day for a
structural class I substance. The mTAMDIs for [FL-no: 14.001, 14.058 and 14.072] are below the
threshold of concern of 90 lg/person per day for the structural class III substances. The mTAMDI
values for [FL-no: 13.134, 14.030, 14.042] are above the threshold of concern of 90 lg/person per
day for the structural class III substances. For the remaining 15 substances, use levels are needed to
calculate the mTAMDIs.
5 Annex III, Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. Ofﬁcial Journal of the European Communities 19.7.2000, L
180, p. 8–16.
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Table 1: Summary of speciﬁcation data (JECFA, 2005a)
FL-no
JECFA-no
EU Register name Structural formula
FEMA no
CoE no
CAS no
Phys.form
Molecular formula
Molecular weight
Solubility(a)
Solubility
in ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refractive Index(d)
Speciﬁc gravity(e)
13.134
1310
1-Furfurylpyrrole N
O 3284
2317
1438-94-4
Liquid
C9H9ON
147.18
Insoluble
Soluble
76–78 (1 hPa)
–
NMR
98%
1.529–1.536
1.078–1.084
14.001
1303
Isoquinoline N 2978
487
119-65-3
Solid
C9H7N
129.16
Slightly soluble
Soluble
242–243
27–29
NMR
97%
1.621–1.627
1.097–1.103
14.004
1304
3-Methylindole HN 3019
493
83-34-1
Solid
C9H9N
131.18
Soluble
Soluble
–
95–97
NMR
97%
n.a.
n.a.
14.007
1301
Indole
H
N 2593
560
120-72-9
Solid
C8H7N
117.15
Insoluble
Soluble
n.a.
51–54
NMR
97%
n.a.
n.a.
14.030
1308
2-Pyridine methanethiol SHN 3232
2279
2044-73-7
Liquid
C6H7NS
125.20
Soluble
Soluble
57–58 (0.8 hPa)
–
NMR
98%
1.573–1.580
1.150–1.157
14.038
1309
2-Acetylpyridine
N
O 3251
2315
1122-62-9
Liquid
C7H7ON
121.14
Insoluble
Soluble
189–193
–
IR NMR
97%
1.518–1.524
1.077–1.084
14.039
1316
3-Acetylpyridine N
O
3424
2316
350-03-8
Liquid
C7H7ON
121.14
Soluble
Soluble
230
–
NMR
97%
1.530–1.540
1.103–1.112
14.041
1314
Pyrrole
H
N 3386
2318
109-97-7
Liquid
C4H5N
67.09
Slightly soluble
Soluble
130–131
–
IR
98%
1.507–1.510
0.955–0.975
N
O
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FL-no
JECFA-no
EU Register name Structural formula
FEMA no
CoE no
CAS no
Phys.form
Molecular formula
Molecular weight
Solubility(a)
Solubility
in ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refractive Index(d)
Speciﬁc gravity(e)
14.042
1302
6-Methylquinoline N 2744
2339
91-62-3
Liquid
C10H9N
143.19
Slightly soluble
Soluble
259
–
NMR
98%
1.611–1.617
1.060–1.066
14.045
1305
2-Acetyl-1-ethylpyrrole
N
O
3147
11371
39741-41-8
Liquid
C8H11ON
137.18
Slightly soluble
Soluble
209–211
–
NMR
98%
1.550–1.556
1.052–1.058
14.046
1306
2-Acetyl-1-methylpyrrole
N
O 3184
11373
932-16-1
Liquid
C7H9ON
123.16
Slightly soluble
Soluble
200–202
–
NMR
98%
1.539–1.545
1.037–1.043
14.047
1307
2-Acetylpyrrole HN
O
3202
11721
1072-83-9
Solid
C6H7ON
109.13
Soluble
Soluble
n.a.
87–93
NMR
97%
n.a.
n.a.
14.058
1311
2-Isobutylpyridine N 3370
11395
6304-24-1
Liquid
C9H13N
135.21
Insoluble
Soluble
181
–
NMR
97%
1.480–1.486
0.894–0.900
14.059
1312
3-Isobutylpyridine N 3371
11396
14159-61-6
Liquid
C9H13N
135.21
Insoluble
Soluble
68–68.5 (10hPa)
–
NMR
97%
1.488–1.494
0.898–0.904
14.060
1313
2-Pentylpyridine N 3383
11412
2294-76-0
Liquid
C10H15N
149.24
Insoluble
Soluble
102–107
–
NMR
97%
1.485–1.491
0.895–0.901
14.061
1315
3-Ethylpyridine
N
3394
11386
536-78-7
Liquid
C7H9N
107.16
Slightly soluble
Soluble
166
–
NMR
98%
1.499–1.505
0.951–0.957
N
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FL-no
JECFA-no
EU Register name Structural formula
FEMA no
CoE no
CAS no
Phys.form
Molecular formula
Molecular weight
Solubility(a)
Solubility
in ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refractive Index(d)
Speciﬁc gravity(e)
14.065
1317
2,6-Dimethylpyridine N 3540
11381
108-48-5
Liquid
C7H9N
107.16
Soluble
Soluble
143–145
–
MS
99%
1.495–1.501
0.917–0.923
14.066
1318
5-Ethyl-2-methylpyridine N 3546
11385
104-90-5
Liquid
C8H11N
121.18
Slightly soluble
Soluble
172–175
–
NMR
97%
1.495–1.502
0.917–0.923
14.068
1319
2-Propionylpyrrole H
N
O 3614
11942
1073-26-3
Solid
C7H9ON
123.16
Slightly soluble
Soluble
n.a.
43–45
IR NMR
99%
n.a.
n.a.
14.071
1320
Methyl nicotinate N
O
O
3709
93-60-7
Solid
C7H7O2N
137.14
Slightly soluble
Soluble
n.a.
38–43
IR NMR MS
98%
n.a.
n.a.
14.072
1321
2-(3-Phenylpropyl)pyridine N 3751
2110-18-1
Liquid
C14H15N
197.28
Insoluble
Soluble
142–143 (1 hPa)
–
IR NMR
97%
1.558–1.563
1.012–1.018
14.164
1322
2-Propylpyridine N 622-39-9 Liquid
C8H11N
121.20
Slightly soluble
Soluble
169–171
–
NMR
98%
1.490–1.496
0.907–0.917
n.a.: not applicable.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
N
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4.2. Biological and toxicological data
4.2.1. Genotoxicity
4.2.1.1. Genotoxicity studies – text taken6 from JECFA (JECFA, 2006a)
In vitro
There was no evidence of mutagenicity in the assay for reverse mutation in bacteria when various
strains of Salmonella Typhimurium (TA97, TA98, TA100, TA102, TA104, TA1535, TA1537, TA1538 and
TM677) were incubated with indole [FL-no: 14.007] at a concentration of up to 30 lmol/plate
(3,515 lg/plate) (Anderson and Styles, 1978; Kaden et al., 1979; Florin et al., 1980; Ochiai et al., 1986;
Vance et al., 1986; Sasagawa and Matsushima, 1991; Fujita et al., 1994), isoquinoline [FL-no: 14.001]
at a concentration of up to 20,000 lg/mL (Sugimura et al., 1976; Nagao et al., 1977; Epler et al., 1979;
Kaden et al., 1979; Sideropoulos and Specht, 1984), skatole [FL-no: 14.004] (4-methylindole) at a
concentration of up to 3 lmol/plate (394 lg/plate) (Florin et al., 1980; Ochiai et al., 1986; Kim et al.,
1989; Sasagawa and Matsushima, 1991), pyrrole [FL-no: 14.041] at a concentration of up to
1.4 mmol/plate (93,926 lg/plate) (Florin et al., 1980; Aeschbacher et al., 1989; Lee et al., 1994) and
3-ethylpyridine [FL-no: 14.061] at a concentration of up to 3 lmol/plate (321 lg/plate) (Florin et al.,
1980) with and without metabolic activation. Methyl 2-pyrrolyl ketone [FL-no: 14.047] (2-acetylpyrrole)
at concentrations of 4 to 100 lmol/plate induced a > 2-fold increase in the number of revertants/plate
compared with the control when tested in S. Typhimurium TA98 in the absence of metabolic activation
(Lee et al., 1994). However, negative results were obtained with metabolic activation as well as in
S. Typhimurium TA100 (both with and without metabolic activation). Furthermore, no mutagenic activity
was reported in either strain when incubated with methyl 2-pyrrolyl ketone at a concentration of up to
200 lg/plate with and without metabolic activation (Wang et al., 1994). 6-Methylquinoline [FL-no:
14.042] at a concentration of 3.3 to 3,600 lg/plate gave uniformly positive results in the presence of
metabolic activation (Sugimura et al., 1976; Nagao et al., 1977; Dong et al., 1978; Wild et al., 1983;
Takahashi et al., 1988; Debnath et al., 1992; Zeiger et al., 1992). Methylquinolines, tested at a
concentration of 400 lg/plate, showed a potent bactericidal or bacteriostatic effect, with only 6%
survival of S. Typhimurium TA100 treated with 6-methylquinoline (Dong et al., 1978).
There was no evidence of mutagenicity when Escherichia coli (strains WP2 uvr4A/pKM101, SD-4-
73, or B/r HCR+) were incubated with indole [FL-no: 14.007] at a concentration of up to 0.4 lmol/
plate (47 lg/plate) (Sasagawa and Matsushima, 1991), isoquinoline [FL-no: 14.001] at a concentration
of up to 50 lg/mL, skatole [FL-no: 14.004] (3-methylindole) at a concentration of up to 0.4 lmol/plate
(52 lg/plate) (Szybalski, 1958; Sasagawa and Matsushima, 1991) or 3-acetylpyridine [FL-no: 14.039]
at a concentration of up to 10,000 mg/plate (Pai et al., 1978).
In non-standardised assays, 2-acetylpyridine [FL-no: 14.038] at 0.50 to 0.87% (54,000 to
93,960 lg/mL) and 3-acetylpyridine [FL-no: 14.039] at 0.5 to 1.11% (55,100 to 122,322 lg/mL)
caused a dose-dependent increase in mitotic aneuploidy in strain D61.M of Saccharomyces ceverisiae
(Zimmermann et al., 1986). At the higher test concentrations, the growth of D61.M was strongly or
completely inhibited. The authors noted that it is generally recognised that there is a threshold dose
for induction of aneuploidy in yeast (Zimmermann et al., 1985a,b,c).
Assays in mammalian cell lines have been performed for isoquinoline [FL-no: 14.001] (Williams,
1984), skatole [FL-no: 14.004] (3-methylindole) (Kim et al., 1989) and pyrrole [FL-no: 14.041]
(Williams, 1984). There was no evidence of increased unscheduled DNA synthesis when freshly
isolated rat liver cells were incubated with pyrrole or isoquinoline (concentrations not speciﬁed)
(Williams, 1984). Single-strand DNA breaks and inhibition of growth were reported when undeuterated
or deuterated (at C2 or C3 positions) 3-methylindole (skatole) at 10 lmol/L to 1 mmol/L (1.31 to
131.18 lg/mL) was incubated with isolated cultured bovine kidney cells. However, there was no
evidence of DNA interstrand crosslinks (Kim et al., 1989). These observations are consistent with
reports that, at high concentrations, indoles deplete glutathione, leading to increased formation of
DNA adducts (Nichols et al., 2000; Regal et al., 2001).
6 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE
has been removed.
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In vivo
There was no evidence for mutation in a standard assay for sex-linked recessive lethal mutation
when adult Drosophila melanogaster were fed 6-methylquinoline [FL-no: 14.042] at a concentration of
10 mmol/L (1,432 lg/mL) in a 5% sucrose solution for 3 days (Wild et al., 1983). Furthermore, 6-
methylquinoline did not induce micronucleus formation in bone marrow cells obtained from male and
female NMRI mice 30 h after treatment with the test compound as a single intraperitoneal dose at 0,
286, 429 or 572 mg/kg bw (Wild et al., 1983).
JECFA’s-conclusion on genotoxicity
Overall, negative results were reported in assays for reverse mutation in bacteria for six representative
pyridine, pyrrole and quinoline derivatives (i.e. indole [FL-no: 14.007], isoquinoline [FL-no: 14.001],
skatole [FL-no: 14.004] (3-methylindole), methyl 2-pyrrolyl ketone [FL-no: 14.047] (2-acetylpyrrole),
pyrrole [FL-no: 14.041] and 3-ethylpyridine [FL-no: 14.061]). Although 6-methylquinoline gave positive
results with metabolic activation, it gave negative results in studies in vivo, indicating that there are
adequate detoxication mechanisms for the rapid absorption, distribution, biotransformation and
elimination of the N-containing heteroaromatic derivatives. 2-Acetylpyridine and 3-acetylpyridine
produced positive results in yeast, but this is unlikely to occur at low doses because yeast is generally
believed to have a threshold for the induction of aneuploidy. The positive results reported in bacteria for
skatole (3-methylindole) are consistent with observations that, at high concentrations, indoles deplete
glutathione, leading to reduced detoxiﬁcation.
On the basis of the available evidence, the 22 pyridine, pyrrole and quinoline derivatives in this
group do not demonstrate genotoxic potential.
For a summary of in vitro/in vivo genotoxicity data considered by JECFA, see Table A.1.
4.2.1.2. Genotoxicity studies – text taken7 from EFSA FGE.24Rev2 (EFSA CEF Panel, 2013)
In vitro/in vivo
Genotoxicity data were provided for seven of the 24 candidate substances. In in vitro studies on the
candidate substances 2-methylindole [FL-no: 14.131], 2-methylpyridine [FL-no: 14.134], 3-methylpyridine
[FL-no: 14.135], 4-methylpyridine [FL-no: 14.136], 2,4-dimethylpyridine [FL-no: 14.104], 3,5-dimethylpyridine
[FL-no: 14.106] and 4-acetylpyridine [FL-no: 14.089] in doses up to 10000 lg/plate, with and without
metabolic activation, did not cause reverse mutations in various strains of S. Typhimurium (Table A.2 in the
present FGE.77Rev3).
Studies on induction of aneuploidy in S. cerevisiae D61.M available for the three candidate
substances 2-methylpyridine [FL-no: 14.134], 2,4-dimethylpyridine [FL-no: 14.104] and 4-acetylpyridine
[FL-no: 14.089] gave positive results. The positive results were obtained at high doses inhibiting the
growth of the yeast. Furthermore, fungal systems for measuring aneuploidy have little relevance
compared to the mammalian system.
No in vivo studies on genotoxicity of the candidate substances were available.
Genotoxicity tests are available for the eight supporting substances [FL-no: 14.004, 14.007, 14.038,
14.039, 14.041, 14.047, 14.061 and 14.065]. 2-Acetylpyrrole [FL-no: 14.047] (methyl 2-pyrrolyl
ketone) was positive in TA98 without metabolic activation at the two highest concentrations tested.
Negative results were obtained at the lowest concentration as well as with metabolic activation. This
study is considered of limited relevance. Pyrrole [FL-no: 14.041], indole [FL-no: 14.007], 3-
methylindole [FL-no: 14.004] (skatole), 3-ethylpyridine [FL-no: 14.061] and 2-acetylpyridine [FL-no:
14.038] were negative in bacterial mutation assays.
Studies on induction of aneuploidy in S. cerevisiae D61.M are available on three supporting
substances, 2,6-dimethylpyridine [FL-no: 14.065], 2-acetylpyridine [FL-no: 14.038] and 3-acetylpyridine
[FL-no: 14.039], which gave positive results. However, as for the three candidate substances, the
positive results were obtained at high doses inhibiting the growth of the yeast. Furthermore, fungal
systems for measuring aneuploidy have little relevance compared to the mammalian system.
In vivo data are available for one supporting substance.
3-Methylindole (skatole) [FL-no: 14.004] was reported negative in the MN assay in mice. The
validity of this study, however, cannot be evaluated, as only an abstract is available.
7 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE
has been removed.
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Positive results were obtained for some candidate and supporting substances in the Rec, DNA
breaking, Chinese hamster ovary (CHO)8 and DNA synthesis assays. These results are, however, not
considered valid.
Conclusion on genotoxicity
The genotoxicity data available for the candidate substances do not preclude their evaluation
through the Procedure.
For a summary of in vitro/in vivo genotoxicity data considered by EFSA, see Tables A.2 and A.3
(Appendix A).
4.2.1.3. Genotoxicity studies evaluated by the panel in FGE.77Rev1
6-Methylquinoline [FL-no: 14.042]
6-Methylquinoline [FL-no: 14.042] was found to induce chromosome aberrations and sister
chromatid exchanges (SCE) in CHO cells (National Toxicology Program (NTP), 1986).
A MN assay was performed by Nakajima (2005) essentially in line with the OECD Guideline 474. No
signiﬁcant increase of micronucleated polychromatic erythrocyte (PCE) frequency was observed in any
groups of BDF1 male mice, treated by gavage at 225, 450 and 900 mg/kg bw for two subsequent
days, 24 h apart. No signiﬁcant decrease in the percentage of polychromatic erythrocytes to the
analysed total erythrocytes (% PCE) was observed in any treatment group (Nakajima, 2005). The lack
of cytotoxicity in the bone marrow cells does not allow a conclusion as to whether the test substance
or a metabolite (e.g. an electrophilic epoxide) reached the bone marrow. Therefore, the results of this
study have to be considered of limited relevance.
A bone marrow MN assay was performed by Honarvar (2004) on a structurally related substance,
6-isopropylquinoline, which was in compliance with good laboratory practice (GLP) and OECD test
guideline 474. No signiﬁcant increase of micronucleated PCE frequency was observed in any group of
NMRI mice orally treated with 6-isopropylquinoline at 500, 1,000 and 2,000 mg/kg bw at 24 h after
treatment and for the highest dose, 2,000 mg/kg bw also 48 h after treatment (Honarvar, 2004).
Slight cytotoxic effects in the bone marrow (less than 10% changes in PCE/normochromatic
erythrocyte (NCE) ratio) were observed, only at the high dose. Also, at the high dose group 48 h after
treatment, the percentage of micronucleated cells (0.118) was higher than the corresponding vehicle
control (0.065). The value was within the historical control range (up to 0.15%). Also in this case, due
to the limited cytotoxicity, it is not clear whether the test substance/metabolite reached the target
(bone marrow) in sufﬁcient concentrations to elicit genotoxic effects.
The results of the MN assay by Honarvar (2004) on the structurally related substance 6-
isopropylquinoline were considered of limited relevance due to the lack of evidence of target tissue
exposure. Therefore, this study could not rule out the concern for genotoxicity for 6-methylquinoline.
For a summary of in vitro/in vivo genotoxicity data on 6-methylquinoline, see Tables A.4 and A.5
(Appendix A).
4.2.2. New genotoxicity studies evaluated in FGE.77Rev3
4.2.2.1. 6-Methylquinoline [FL-no: 14.042] – in vivo comet assay
6-Methylquinoline [FL-no: 14.042] (purity 99.9%) was tested for genotoxicity in vivo in male Han
Wistar rats by assessing its ability to induce DNA damage in the liver and duodenum using the Comet
assay (Keig-Shevlin, 2016). An additional separate experiment was conducted in the liver to clarify
increases in tail intensity observed in the ﬁrst experiment. The studies were in compliance with GLP
and OECD test guideline 489 (OECD, 2014).
Doses were selected based on a range-ﬁnder experiment, where two doses of 6-methylquinoline
[FL-no: 14.042] of 400 and 600 mg/kg bw per day were administered at 0 and 21 hrs to both male
and female rats. No gender differences were observed for toxicity; therefore, only male rats were
treated in the main experiments. The dose of 400 mg/kg bw per day was considered as an estimate of
the maximum tolerated dose (MTD), based on clinical signs (ataxia, piloerection, decreased activity)
observed. Based on this range-ﬁnder experiment, the following doses were tested in the main
experiments: 0, 100, 200 and 400 mg/kg bw per day (six animals per group).
8 This refers to a chromosomal aberration assay using CHO cells, where positive results were obtained at concentrations that
show marked inhibition of DNA synthesis (Table A.2).
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In the main experiments, 6-methylquinoline was administered twice to male Han Wistar rats by
gavage at 0 (day 1) and 21 h (day 2). Vehicle (corn oil) and positive control (ethyl methanesulfonate
(EMS), 200 mg/kg bw per day) groups were included. Tissues were sampled on day 2, 24 h after the
ﬁrst treatment.
No clinical signs of toxicity were observed following treatments with vehicle control, 6-
methylquinoline or the positive control. There were no changes in clinical chemistry and no
macroscopic or microscopic changes related to administration of 6-methylquinoline.
Experiment 1 – Comet assay in liver
Dose-related increases in group mean %tail intensity in the liver were observed in all test article
treated groups. No dose-related increase in %clouds was observed. At the intermediate and high
doses, the increases in tail intensity were statistically signiﬁcant and a positive linear trend was also
apparent (p ≤ 0.01). At 100 mg/kg bw per day, tail intensity and tail moment values were comparable
with the vehicle control animals. At 200 mg/kg bw per day, a two-fold increase in group mean tail
intensity and tail moment was observed. At 400 mg/kg bw per day, the group mean tail intensity and
tail moment were three-fold higher than the vehicle control. The author of the study considered that
this result was mainly due to two animals displaying elevated tail intensity and tail moment values
which increased the group mean. As all individual animal data were within the laboratory’s historical
control data and in the absence of any clinical chemistry or pathological changes in the liver which
could be considered to be due to toxic effects of the test article, the biological relevance of these
statistically signiﬁcant increases in tail intensity was unclear. Therefore, the experiment in liver was
repeated to check the reproducibility of these results.
The Panel considered the results of this experiment as positive taking into account that two criteria
for evaluation and interpretation of results as positive (OECD test guideline 489) were fulﬁlled:
a) at least one of the test doses exhibits a statistically signiﬁcant increase compared with the
concurrent negative control,
b) the increase is dose related when evaluated with an appropriate trend test.
The third criterion (‘any of the results are outside the distribution of the historical negative control
data for a given species, vehicle, route, tissue, and number of administrations’) is not applicable in this
case because the range for historical negative controls is very wide (95% reference range of
0.08–5.08%).
Experiment 1 – Comet assay in duodenum
Following treatment with 6-methylquinoline at all dose levels, there was no evidence of any
induction of DNA damage in cells isolated from duodenum. The group mean %tail intensity and tail
moment values were comparable to the concurrent vehicle control group. No dose-related increase in
%clouds in duodenum was reported following treatment with 6-methylquinoline.
Experiment 2 – Comet assay in liver
Group mean %tail intensity and tail moment values for all groups of animals treated with 6-
methylquinoline were comparable with the group mean vehicle control data. There were no statistically
signiﬁcant differences in %tail intensity between treated and control groups. All individual animal data
at all dose levels were generally consistent with the vehicle control animals and fell within the
laboratory’s historical control data. There was no dose-related increase in %clouds in liver following
treatment with 6-methylquinoline.
The increases in liver group mean tail intensity observed in experiment 1 were not reproduced in
experiment 2. The authors of this study considered that the statistically signiﬁcant increases in group
mean liver tail intensity observed in the ﬁrst experiment were due to chance occurrence in individual
animals increasing the group means, rather than a true genotoxic effect and that there was no
reproducible evidence that exposure of animals to 6-methylquinoline induced DNA damage in cells
isolated from the liver.
Conclusion on comet assay
The Panel considered that the in vivo comet assay in rats (Keig-Shevlin, 2016) reported negative
results in duodenum and equivocal results in liver, showing positive results in a ﬁrst experiment, not
reproduced in a second one. The Panel requested the applicant to clarify these results. The transgenic
rodent gene mutation assay was considered as appropriate test for the in vivo follow-up of in vitro
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positive results in bacteria (EFSA Scientiﬁc Committee, 2011) In addition, a combined analysis of MN in
peripheral blood in the same animals was requested to conﬁrm the negative in vivo data observed in
studies on chromosomal damage (Wild et al., 1983; Nakajima et al., 2005) which were considered by
the Panel to be of only limited reliability.
4.2.2.2. 6-Methylquinoline [FL-no: 14.042] – in vivo gene mutation assay and
micronucleus assay in MutaTM Mice
6-Methylquinoline (purity 99.9%) was tested for its ability to induce gene mutations in the lacZ
transgene in liver and duodenum from treated male MutaTM Mice (CD2-lacZ80/HazfBR strain). In
addition, an assessment of MN induction in peripheral blood reticulocytes from the same animals was
included (Ballantyne, 2017).
Based on a range-ﬁnder experiment where no gender difference was observed, the MTD was
established (500 mg/kg bw per day) for the main experiment based on clinical signs of toxicity (e.g.
hunched posture, piloerection, semi-closed eyes, raised skin and fur, reduced activity and staggering).
Groups of seven male mice were administered 6-methylquinoline, by oral gavage, at 0, 125, 250 or
500 mg/kg bw per day for 28 days. No positive control was included in the dosing regimen of this
study, but was provided from another study carried out in the same laboratory measuring the same
endpoints (positive control: ethylnitrosourea animals dosed at 10 mg/kg bw per day). The 28-day
dosing period was followed by 3 days expression time before necropsy at day 31. On day 29, blood
samples were collected from the tail vein of all the animals for the MN assay. After a 3-day expression
period following the ﬁnal dosing (day 31), the animals were sacriﬁced. All animals were macroscopically
examined and the liver and duodenum were collected for the mutant frequency assay.
Mutant frequency in duodenum and liver
DNA was obtained from duodenum and liver tissues from all four treatment groups as well as
frozen positive control DNA from animals treated with ethylnitrosourea from another study of the same
laboratory for the mutant frequency assay. The DNA was packaged into phage heads ready to
transfection in suspensions of E. coli, according to the OECD test guideline 488 (OECD, 2013). The
transfected E. coli was plated, incubated and scored for plaques. According to the study report, all
accepted packaging reactions resulted in at least 30,000 plaque-forming units (pfu) and at least one
mutant plaque. All reported mutation data were generated for at least 200,000 pfu per tissue per
animal, from at least three independent packaging reactions. At least 1 million pfu were obtained per
group, per tissue from a minimum of ﬁve animals.
No statistically signiﬁcant increases in mutant frequency were observed either in the liver or
duodenum of treated MutaTM Mice, and all study results were within the laboratory’s historical control
data set.
Micronucleus assay
Blood samples taken on day 29 were analysed for MN frequency by high speed ﬂow cytometry. At
least 20,000 reticulocytes from each sample were scored for MN.
No positive control was included in the MN experiment, but positive control blood samples
(cyclophosphamide at 20 mg/kg bw per day) from another study of the same laboratory were
analysed alongside the study samples. No signiﬁcant increase in the frequency of micronucleated cells
was observed in the peripheral blood reticulocytes of mice from any of the 6-methylquinoline treated
groups compared to the vehicle controls. According to the author of the study report, all data fell
within the historical control data set for the laboratory, but no historical control data were provided for
animals dosed for more than seven days.
Conclusion on the in vivo gene mutation assay and in vivo micronucleus assay
The Panel concluded that under the conditions of this study, 6-methylquinoline did not induce
mutations in the liver and duodenum of MutaTMMice, following treatment for 28 days up to the dose of
500 mg/kg bw per day (the MTD estimated for this study) and that the substance did not induce
micronucleated cells in peripheral blood reticulocytes. In this study, no toxicity in liver and bone
marrow was observed that would be considered as a direct evidence of tissue exposure to the tested
substance. However, the clinical signs of toxicity observed in the dose range-ﬁnding study such as
changes in behaviour (hunched posture, reduced activity and staggering), observed at high and mid
doses) suggest that animals were systemically exposed to 6-methylquinoline, and this is considered as
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a line of evidence of target tissue exposure (liver and bone marrow), on the basis of the criteria
reported in the recent opinion of the EFSA Scientiﬁc Committee (EFSA Scientiﬁc Commitee, 2017).
The Panel considered this line of evidence, together with the observation that several other
quinoline derivatives produce toxicity in liver and other tissue, sufﬁcient to assume that 6-
methylquinoline is systemically bioavailable and that, therefore, the negative results of the gene
mutation assay in liver and the MN assay in peripheral blood are conclusive.
For a summary of in vivo genotoxicity data on 6-methylquinoline, see Appendix A, Table A.5.
4.2.2.3. EFSA considerations on genotoxicity
The Panel concluded that one of the 22 substances evaluated by JECFA, 6-methylquinoline [FL-no:
14.042], showed a genotoxic potential in vitro, with consistently positive results in several bacterial
mutagenicity tests, after metabolic activation. Increases of chromosomal aberrations and sister
chromatid exchanges in CHO cells were reported in a summary table (NTP, 1986), but were considered
inadequate for the evaluation due to high level of toxicity at all the concentrations tested and the low
number of metaphases examined.
6-Methylquinoline was reported negative in a test for gene mutations in Drosophila (Wild et al.,
1983).
Negative results were also reported in two in vivo MN studies in mice considered of limited relevance.
In the ﬁrst one (Wild et al., 1983), carried out by single ip administration, a single sampling time was
used. In a more recent one, by gavage, no toxicity to the bone marrow was observed, although some
weak evidence of systemic exposure of the animals was provided by clinical signs (reduction of
spontaneous activity, prone position) reported at the highest dose tested (Nakajima, 2005).
The in vivo comet assay in rats reported negative results in duodenum and equivocal results in liver,
showing a dose-related increase in %tail intensity in liver in a ﬁrst experiment, which was not
reproduced in a second one (Keig-Shevlin, 2016).
A transgenic gene mutation assay in MutaTMMice (Ballantyne, 2017) carried out in liver and
duodenum of animals treated with 6-methylquinoline for 28 days up to 500 mg/kg bw per day, the
MTD, did not show any increase of mutant frequency. Therefore, the Panel considered that the
concern for gene mutation is ruled out.
The analysis of MN in peripheral reticulocytes of the same animals after 28 days of treatment
(Ballantyne, 2017) did not result in any increase in cells with MN compared to the control group.
Therefore, the Panel considered that the concern for structural and numerical chromosomal
aberrations is ruled out, likewise.
Based on the data available, the Panel concluded that there is no concern for genotoxicity of 6-
methylquinoline [FL-no: 14.042].
For 21 JECFA evaluated pyridine, pyrrole and quinoline derivatives, the Panel concluded previously
that the data available do not preclude evaluation through the Procedure. Based on the new data
provided recently, the Panel concluded that also 6-methylquinoline [FL-no: 14.042] can now be
evaluated through the Procedure.
4.2.3. Repeated dose toxicity studies
Since the publication of FGE.77 (EFSA, 2009), additional toxicity data have been provided for
isoquinoline [FL-no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047], the latter
also to cover the evaluation of the structurally related 2-propionylpyrrole [FL-no: 14.068]. The main
studies provided are for each substance a 90-day study. Since the publication of FGE.77Rev1 (EFSA
CEF Panel, 2014), additional toxicity data were provided for 1-furfurylpyrrole [FL-no: 13.134]. The
main study provided is a 90-day study; these data are intended to cover the re-evaluation of this
substance and 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no: 14.046]
and have been evaluated in FGE.77Rev2 (EFSA CEF Panel, 2015). In the present revision of FGE.77
(FGE.77Rev3), data from a 90-day study and from a carcinogenicity study on 6-methylquinoline
[FL-no: 14.042] are evaluated.
The available toxicity studies are summarised in Appendix B, Table B.1.
4.2.3.1. Isoquinoline [FL-no: 14.001]
A 90-day oral study in rats was performed on isoquinoline according to the Japanese ‘Guidelines for
designation of food additives and revision of standards for use of food additives, Notiﬁcation No 29’ of
the Environmental Health Bureau, Ministry of Health and Welfare, Japan, 22 March 1996. The
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requirements of this guideline are very similar to the OECD Guideline 408. It is a GLP study. Groups
(10/sex per dose) of male and female Sprague–Dawley rats were administered 0 (vehicle control),
0.03, 0.3 and 3 mg/kg bw per day of isoquinoline dissolved in corn oil by gavage daily for 90 and 91
days for males and females, respectively (Kojima, 2006). The purity of the test article was 98.5%.
Animals were weighed at the start of the study and weekly thereafter. Food consumption and
efﬁciency were measured weekly. The rats were caged individually during the experiment. All animals
were subject to ophthalmologic examination prior to the start of the study, and on day 79, ﬁve animals
of each sex per group were examined again. Urine was analysed on day 82 for ﬁve animals from each
group. The rats were fasted for 18–21 h prior to blood sampling immediately prior to necropsy. A full
haematological and biochemical analysis of blood was performed. At termination of the study, animals
were sacriﬁced and subject to full necropsy. Histopathological examination was performed on all
organs (as in the OECD Guideline 408) for the control and high dose group.
No animals died through the course of the study. No clinical signs of toxicity or behavioural changes
were observed. Ophthalmological examination revealed no treatment-related changes. Mean body
weights were comparable throughout the study between control and test groups of both sexes. Urine
analysis did not reveal any treatment-related alterations when compared to controls. Haematology and
blood chemistry results showed no signiﬁcant differences between the test groups and controls. There
were no organ weight changes or other macroscopic ﬁndings attributable to the administration of the
test substance.
Histopathological examination did not show differences between controls and treated animals of
either sex; some incidental ﬁndings occurred in both controls and treated animals, but there was no
signiﬁcant difference in their occurrence or intensity in the various organs when compared to the
control groups.
Since there were no statistically signiﬁcant changes due to the administration of the test material,
the NOAEL of isoquinoline was determined to be 3 mg/kg bw per day in male and female rats after 90
days of administration by oral gavage (Kojima, 2006).
4.2.3.2. Pyrrole [FL-no: 14.041]
In a gavage study (Marumo, 2008), groups (10/dose per sex) of male and female Sprague–Dawley
rats were administered 0 (vehicle control), 0.03, 0.30 and 3.00 mg/kg bw of aqueous pyrrole daily, by
gavage for 90 days prior to necropsy. This study was performed according to ‘Guidelines for
designation of food additives and for revision of standards for use of food additives’, Notiﬁcation No.
29 of the Environmental Health Bureau, the Ministry of Health and Welfare, Japan, 22 March 1996
which is comparable to an OECD Guideline 408 study. It is a GLP study. Clinical observations were
recorded daily and body weights and food consumption were recorded weekly. On day 79, ﬁve animals
from each group were subject to ophthalmology examination. Urine samples were collected on day 82
for routine clinical chemical analysis. At termination, blood samples were taken for clinical chemistry
determinations and haematological examination. At necropsy, organ weights for all organs required for
an OECD Guideline 408 study were recorded. Tissues from all organs required in an OECD Guideline
408 study from both sexes of the control and 3.00 mg/kg bw per day groups were ﬁxed and
preserved for histopathological examination.
No mortality was observed throughout the course of the study and the general condition of the rats
was unremarkable. Mean body weight gains and food consumption were comparable across test and
control groups. Ophthalmologic examination revealed that in some animals in all male groups, controls
included and some females of the 0.03 and 3.00 mg/kg bw per day groups, corneal clouding was
observed.
Urine analysis revealed no toxicologically signiﬁcant ﬁndings except that one male rat out of ﬁve in
the 3.00 mg/kg bw per day group showed some changes, suggesting a possible kidney effect at that
level; however, there were no indications of kidney pathology in the histopathological ﬁndings of this
rat. In the females, there were no effects observed in urinalysis except that they showed signiﬁcantly
higher concentrations of sodium, potassium and chloride ions, but this was not dose dependent. Males
and females in the 3.00 mg/kg bw per day groups showed an increase in ‘urobilinogen concentrations’
in blood, but this was not accompanied by associated histopathology in the liver, spleen, bone marrow
or haemolysis; the effect can be attributed to the interference of pyrrole present in urine in the
colorimetric assay; it gives the same reaction as urobilinogen in the detection method used.
In female rats, the white blood cell count was lower for all three exposure levels than the control
group, but this showed no dose relationship; the values were 4,600  1,500, 3,600  900,
3,400  800 and 3,400  1,100 per lL, respectively. At the two higher dose levels, this was
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statistically signiﬁcant (p < 0.05). None of the other haematological parameters was changed as
compared to controls. In male rats, there was no difference in white blood cell levels or any other
haematological parameter. Small changes in blood biochemical ﬁndings in male rats at the highest
exposure were considered incidental.
Gross pathology examination revealed some organ weight variations including decreased absolute
and relative pituitary gland weights only in low-dose treated male rats. All groups of male rats showed
a somewhat decreased relative seminal vesicle weight due to a combination of increased body weight
in the treated rats in combination with a slight decrease in absolute seminal vesicle weight. However,
histopathology did not reveal abnormalities, neither in pituitary gland nor in seminal vesicles.
Histopathological examination was performed on all high dose and control animals, along with any
tissues with lesions at other doses. In the lungs, alveolar accumulation of foamy cells was observed in
eight males and three females at the 3.00 mg/kg bw dose and in four male controls. Mineralisation of
the pulmonary arterial wall was reported for ﬁve males and two females of the high-dose group and
two male controls. Focal thickening of alveolar septum with neutrophilic inﬁltration was seen in two
high-dose male rats. Basophilic tubules were noted in the kidney cortex of eight males and ﬁve
females of the high-dose group and ﬁve females of the control group. Atrophy of the seminiferous
tubule was observed in two male in the high dosed group, but the changes were very slight. In female
in the high dosed group, single animals showed follicle cysts or retention of the corpus luteum with a
marked decrease of eosinophils in the endometrium and myometrium or marked muciﬁcation of the
vaginal mucosa. Most of these phenomena were observed in both the treated and the control groups,
and they are, therefore, considered incidental ﬁndings.
The lower white blood cell count in the females is considered an incidental ﬁnding and not
considered an adverse effect since the count of all other blood cells types was normal in the female
treated groups. In the males, no lower blood count for any cell types was observed, the
histopathological examination revealed no correlating changes in the haematopoietic tissue and there
was no dose–effect relationship (raising the question whether the control value was incidentally too
high; the company, unfortunately, did not give an indication of historical control values in their report).
The Panel decided, based on the ﬁndings, that the NOAEL level was the highest exposure level
3.0 mg/kg bw per day.
4.2.3.3. 2-Acetylpyrrole [FL-no: 14.047]
A 14-day range ﬁnding study
In a 14-day range-ﬁnding dietary study (Bauter, 2012a), groups (3/sex per dietary intake level) of
male and female Sprague–Dawley rats were fed a diet designed to provide 0 (dietary control), 1,000,
9,000 and 18,000 mg/kg feed of 2-acetylpyrrole [FL-no: 14.047] daily. These estimated dietary levels
correspond to the measured intake of 0, 85, 550 and 842 mg/kg bw per day for males and 0, 91, 582
and 949 mg/kg bw per day for females, respectively. Clinical observations were recorded daily and
body weights were recorded on days 0, 7, 11 and 12. Individual food consumption was recorded on
days 7 and 12. Due to increasing mortality in the high intake groups of both sexes, the study was
terminated early at day 12. The results showed that the two higher doses were too toxic for a 90-day
study. A 90-day study was started at lower exposure levels.
Effect on urinary iron excretion
The company also studied the effect of 2-acetylpyrrole [FL-no: 14.047] on urinary excretion of iron
because 2-acetylpyrrole is a strong-complexing agent of metal ions. At a very high dose gavage study
in rats (375 mg/kg bw orally for 10 days), the urinary excretion of total iron was increased six-fold
(Mendes, 2012); no data are provided on absorption of iron from the intestinal tract, which might be
inﬂuenced by complexation of iron with 2-acetylpyrrole.
90-day study
In an OECD test guideline 408 compliant 90-day study, groups of rats (10/sex per dietary intake
level) of male and female Sprague–Dawley CD rats were fed a diet designed to provide 0 (dietary
control), 1,050, 2,100 and 4,200 mg 2-acetylpyrrole [FL-no: 14.047]/kg feed daily (Bauter, 2012b).
These dietary levels correspond to the calculated average daily intakes of 0, 68, 133 and 263 mg/kg
bw for males and 0, 79, 155 and 298 mg/kg bw for females, respectively.
The test material was not stable in the diet, and in the report (Bauter, 2012b), it is suggested that
part of it was probably not detected by the extraction method employed due to complexation with
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metal ions in the feed. It is calculated that over the course of the study, the animals received
concentrations of 35–40% of the target intake level on average. Therefore, values for exposure levels
based on the measured intake are proportionally lower. Based on this analysis of the test diets, the
mean daily intakes were calculated to be 367, 754 and 1,705 mg/kg feed. Assuming that the toxicity is
only related to the free 2-acetylpyrrole, these dietary concentrations correspond to average daily
intakes of 24, 48 and 107 mg/kg bw for males and 28, 56 and 121 mg/kg bw for females,
respectively, over 90 days.
Clinical observations of toxicity were performed on day 0 and weekly until sacriﬁce. Animals were
weighed on day 0 at the start of the study and weekly thereafter. Food consumption and efﬁciency
were measured and calculated weekly. Blood chemistry and haematology were performed on blood
drawn via sublingual bleed at day 43 for the controls and high intake groups and at day 86 for all
groups after overnight fast. Urine was collected during the 15 h prior to the blood draw. Prior to
initiation of the study and on day 91, the eyes of all rats were examined by focal illumination and
indirect ophthalmoscopy. At termination of the study, all survivors were sacriﬁced and subject to full
necropsy and histopathology as required by the OECD Guideline.
There were no mortalities or ophthalmological changes associated with the presence of 2-acetylpyrrole
in the diet. Most other ﬁndings, generally also noted in control animals, were not considered adverse
effects of test substance administration and were regarded as incidental. Statistically signiﬁcant
concentration-dependent reductions in body weight, body weight gain, food consumption (males and
females) and food efﬁciency (females) at the highest dietary level (1,705 mg/kg feed measured
concentration) during the study were attributed to the possible decrease in test substance palatability at
high dietary levels.
Haematology parameters for both males and females were mostly unchanged during treatment.
Although incidentally reaching a statistically signiﬁcant difference when compared to concurrent
controls, the values were in general within the range of historical controls and without associated
histopathology correlate; they were, therefore, considered to be incidental and not related to the test
material. However, statistically signiﬁcantly (p < 0.05) decreased total white blood cell counts,
erythrocyte counts, haemoglobin concentrations, haematocrit, absolute lymphocyte counts, absolute
monocyte counts and absolute basophil counts and increased red cell distribution width were reported
in the high intake group females on day 86. These parameters are outside of historical control levels
although the variations are low in magnitude. There were no meaningful differences in coagulation
parameters between test and control groups of both sexes.
Variations in clinical chemistry parameters were considered incidental and unrelated to the presence
of 2-acetylpyrrole in the diet due to lack of concentration dependence or correlated pathology.
Organ weight measurements, absolute and relative brain weight, for males were comparable to
controls, with some isolated exceptions; these were without histologic correlate and were considered
unrelated to test substance in the diet.
Female rats of the high intake groups displayed minimal to moderate dark bilateral thyroid glands.
Microscopic changes were slight thyroid hypertrophy/hyperplasia among 4/10 and 10/10 high intake
group males and females, respectively. This was characterised by enlarged subgross tall columnar
appearance of the follicular epithelial cells which appeared with ﬁne cytoplasmic vacuolation with
intermittent focally piled papillary projections into the follicular lumen. The company did not provide a
clear (mechanistic) explanation for this ﬁnding.
In conclusion, although some haematology and clinical parameter changes were observed in mid-
and high-dose groups, in the mid dose group were considered incidental and not of concern (not dose
related and/or very small in magnitude and/or within historic controls and without histopathology
correlation). However, the thyroid effects at the exposure level are of concern as well as the
haematological changes in the high dose group females. Therefore, a NOAEL for 2-acetylpyrrole is
derived from the middle dose 48 mg/kg bw per day in males and 56 mg/kg bw per day in females.
The NOAEL value of 48 mg/kg bw per day is used in calculating the margin of safety.
Metabolites of 2-acetylpyrrole
Mendes (Mendes, 2012) analysed the urine obtained in metabolism cages from rats dosed with 2-
acetylpyrrole [FL-no: 14.047] at 375 mg/kg by oral gavage as described above. Based on gas
chromatography-mass spectroscopy (GC-MS) analysis, three major components were identiﬁed in the
urine of both males and females treated with 2-acetylpyrrole. Unchanged 2-acetylpyrrole and pyrrol-
2,5-dione were detected; the structure of another main metabolite detected in the urine is proposed to
be 1,5-dihydropyrrol-2-one; however, further experiments have yet to be performed to conﬁrm this.
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4.2.3.4. 1-Furfurylpyrrole [FL-no: 13.134]
A 14-day range ﬁnding study
In a 14-day palatability and range-ﬁnding dietary study (Kappeler, 2013a), 1-furfurylpyrrole [FL-no:
13.134] was administered to male and female Crl:CD(SD) rats (3/sex per group) for 14 consecutive
days in the diet to provide 0, 25, 75 and 200 mg/kg bw per day (Kappeler, 2013a). Observations for
mortality and morbidity were performed twice daily and clinical examinations were performed once
daily. Detailed physical examinations including body weight measurements were performed within
4 days of receipt, on the day of randomisation, prior to dosing on study day 0 (body weights, only)
and weekly during the study. Food consumption was recorded 1 week prior to randomisation, on the
day of randomisation and weekly throughout the study. Based on food consumption measurements,
the calculated doses of 1-furfurylpyrrole were 0, 29, 84 and 211 mg/kg bw per day, respectively, for
males and 0, 27, 81 and 192 mg/kg bw per day, respectively, for females over the entire study. All
animals survived the 14 days of diet administration.
There were no overt adverse effects from 1-furfurylpyrrole administration. The only differences
from control group animals were body weight reductions of 18% and 16% for males and females,
respectively, in the 200 mg/kg bw per day group, that were associated with lower food consumption
levels. It was concluded that 1-furfurylpyrrole was well tolerated in Crl:CD(SD) rats at dietary levels of
up to 84 mg/kg bw per day and 81 mg/kg bw per day for males and females, respectively.
90-day study
In an OECD test guideline 408 compliant 90-day dietary study (GLP), 1-furfurylpyrrole [FL-
no:13.134] (purity 99.6%) was administered to individually housed Crl:CD(SD) rats (10/sex per group)
at levels calculated to provide nominal doses of 0, 25, 75 and 150 mg/kg bw per day (Kappeler,
2013b). All animals were subject to observations for mortality and morbidity twice daily, daily clinical
examinations and weekly detailed physical examinations, including body weight and food consumption
measurements. Ophthalmic examinations were performed before the start of the study and in week
12. Clinical pathology parameters (haematology, coagulation, serum chemistry and urinalysis) were
evaluated for all animals at the scheduled necropsy, after 13 weeks of treatment. Blood for
haematology and serum chemistry was collected at necropsy after overnight fast and urine was
collected overnight prior to necropsy. Coagulation was measured in blood collected from anaesthetised
animals prior to sacriﬁce. All tissues were examined microscopically for animals of the 150 mg/kg bw
per day groups. In addition, liver, spleen and nasal tissues were also examined for animals of the two
lower intake level groups.
Based on food consumption data, the mean intake of 1-furfurylpyrrole was calculated to be 25, 77
and 154 mg/kg bw per day for males and 25, 75 and 151 mg/kg bw per day for females. All animals
survived to the end of the study. There were no differences between treated and control groups noted
in clinical observations, macroscopic ﬁndings or urinalysis, except for an increase in urobilinogen
concentration.
By the time of necropsy, body weights were lower in the 150 mg/kg bw per day dose group for
both males (17%) and females (11%) and in the 75 mg/kg bw per day dose group of females
(8%), relative to the control group. Decreased food consumption was also observed. These
decreases were statistically signiﬁcant for the male group at 150 mg/kg bw per day beginning on the
ﬁrst week and throughout the length of the study; for the female groups, the decrease was not
statistically signiﬁcant, although the weight gain in these females was decreased statistically
signiﬁcant. Slightly lower body weights were noted in the 25 and 75 mg/kg bw per day males and the
25 mg/kg bw per day females (4%, 5% and 6%, respectively).
Reductions in red blood cell counts (0.6%, 7.0*% and 9.3**%), haemoglobin levels (3.6%, 5.4*%
and 9.6**%) and haematocrit values (3.7%, 7.2*% and 9.9**%) and slightly higher red blood cell
distribution widths (4.1%, 4.9**% and 4.1**%) were observed in all treated groups (25, 75 and
150 mg/kg bw per day, respectively) of males but were not observed in females. The effect at the
lower exposure level was considered minor. Histopathology showed no changes in bone marrow at
the highest dose level. Pigment deposits in the red pulp of the spleen were minimally increased only at
the highest dose level in eight out of 10 males; for females, this was one out of 10 at the middle dose
and four out of 10 at the highest dose.
* signiﬁcant at 0.05 according to Dunnett’s test.
** signiﬁcant at 0.01 according to Dunnett’s test.
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In males, dose-dependent changes in serum chemistry values included higher total bilirubin
(0.01  0.03, 0.02  0.04, 0.07  0.05** and 0.08  0.04** mg/dL, respectively), which might be
related to the reduced red blood cell counts and cholesterol (39*, 84** and 91**%, respectively). In
females, similar increases were not dose dependent: 0.04  0.05, 0.09  0.03**, 0.11  0.03** and
0.10  0.00** mg/dL) for total bilirubin and 41**, 33* and 66**% for cholesterol. In parallel with the
higher total bilirubin levels, the urobilinogen concentration in urine was increased at the higher dose
levels. Only at the highest dose, sorbitol dehydrogenase (SDH) values in both sexes were increased by
111** and 33% in males and females, respectively.
The increases in total bilirubin and cholesterol suggest effects on the liver. Higher mean liver
weights relative to ﬁnal body weight were noted in the male (6, 16** and 32**%) and female groups
(12**, 17** and 32**% increase based on body weight). Centrilobular hepatocellular vacuolation was
observed in the 75 and 150 mg/kg bw per day male groups and the 150 mg/kg bw per day group
females only. The male groups scored 5/10 minimal and 5/10 mild at the highest dose; 4/10 minimal
and 1/10 mild at the middle dose; 0/10 at the lowest dose; against 0/10 in the controls; the females
showed only at the highest dose in 7/10 centrilobular vacuolisation against 0/10 in the control and
both lower dose groups.
Other microscopic changes were identiﬁed in nasal sections and spleen. In the spleen, ﬁndings were
limited to a very minimal increase in pigment deposits that were mainly restricted to the 150 mg/kg bw
per day dose group. Microscopically, changes in nasal tissue included olfactory mucosa degeneration,
depleted mucous secretion by goblet cells and thin deposits of a hyaline material along the surface of the
olfactory epithelial cells. Olfactory mucosa degeneration was observed in both sexes at the 75 and
150 mg/kg bw per day intake levels and was slightly more prevalent and severe in males. The ﬁndings in
the olfactory mucosa were considered to be adverse. Depleted mucous secretion by goblet cells was
especially prominent in Nasal Section I and was observed in most rats administered 1-furfurylpyrrole.
It is concluded that exposure to 1-furfurylpyrrole [FL-no: 13.134] in the diet for 90 days resulted in
adverse effects in the 75 and 150 mg/kg bw per day groups of males and females and consisted of
effects on liver, red blood cells and olfactory mucosa. Therefore, the NOAEL of [FL-no: 13.134] was
25 mg/kg bw per day for male and female Crl:CD(SD) rats.
4.2.3.5. 6-Methylquinoline
6-Methylquinoline [FL-no: 14.042] was tested in a single-dose 90-day dietary study in Charles River
CD rats (10–16 animals/sex per group) (Posternak et al., 1969). This publication is a summary of 90-
day studies on 42 ﬂavouring compounds. The publication states that ‘of these, 29 were at least 98%
pure (..) the purity of the remainder was 90% or more’; the purity of 6-methylquinoline is not
speciﬁed. The only available information on that study is a brief description of the method employed
and a few general remarks. No study report or any details are available. The study results were
submitted to a FEMA Expert Panel (before 1969).
A control and a single treatment group of the same sex were housed in pairs and given ad libitum
access to water and food. The concentration of the test material in the diet was adjusted during the
study to maintain a dietary intake of 2.2 mg/kg bw per day and 2.7 mg/kg bw per day in males and
females, respectively. Food consumption and body weights were determined weekly. Limited
haematology and blood urea analyses were conducted during the weeks 7 and 13 of the study, on half
of the animals. At the end of the study, animals were sacriﬁced, liver and kidney weights were
measured and ‘gross and histological examinations were carried out on a wide range of organs’.
The authors claim that at the exposure of 2.2 mg/kg bw per day in males and 2.7 mg/kg bw per
day in females, 6-methylquinoline did not induce any effects in the parameters measured. However,
the procedure of the 90-day study is very deﬁcient compared to the current requirements for 90-day
study according to OECD test guideline 408; moreover, the reporting is extremely deﬁcient.
Carcinogenicity study on 6-methylquinoline
Fukushima et al. (1981) reported results from a 2-year oral carcinogenicity study on
6-methylquinoline in the rat. These data are part of a study which investigated the carcinogenicity of
six quinoline derivatives including 8-nitroquinoline as positive control. In the publication by Fukushima
et al. (1981), few study details are reported.
The compounds were mixed with the diet at 0.05%, except for the positive compound,
8-nitroquinoline, which was added at 0.10%. Thus, only one exposure level was tested in groups
consisting of 43–46 animals per sex per group. Since pneumonia occurred during the last 12 weeks of
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the experiment, many rats died prematurely. The surviving animals were necropsied after 104 weeks
and ‘all organs’ were examined histologically. No details about the tissues examined are given.
In the 8-nitroquinoline-treated animals, extensive changes in the forestomach were observed in
both males (n = 30) and females (n = 37): hyperplasia, papilloma and squamous cell carcinoma were
seen in 97, 93 and 67%, respectively, of the males, and 97, 97 and 65% of the females. In addition,
30% (males) and 38% (females) had urinary bladder tumours and 8% of the females had a uterus
carcinoma; in controls (n = 31 and 44 for males and females, respectively), the incidence of these
tumours was 0%. Other tumours were of similar frequency as in controls.
For 6-methylquinoline (n = 38 and 37 for males and females, respectively, dose level: 500 mg/kg
feed which is equivalent to 25 mg/kg bw per day), no differences with controls were observed; only
the frequency of liver hyperplastic nodules seemed increased compared to controls: 10% vs. 0% in
males and 13% vs. 7% in females.
These results show that the study did pick up signs of carcinogenicity for 8-nitroquinoline, while
6-methylquinoline was negative. The exposure level to these two substances was different: 0.10% in
the feed for 8-nitroquinoline vs. 0.05% in the feed for 6-methylquinoline.
4.3. Other studies
Assay for tumour initiation
Quinoline and seven monomethylated derivatives, including 6-methylquinoline, were tested for
tumour-initiating activity on SENCAR female mice skin with promotion by tetradecanoyl phorbol acetate
(La Voie et al., 1984). The total initiation dose of either quinoline or the isomeric methylquinolines was
7.5 mg per mouse.
Quinoline induced tumours in 53% of the mice (on average 0.73 skin tumours per animal); a similar
tumorigenic potential was observed for 4- and 8-methylquinoline (45% of the mice, with an average
skin tumours per animal of 0.90 and 0.66, respectively). No statistically signiﬁcant increases of skin
tumours were observed for 2-, 3-, 5-, 6- and 7-methylquinoline.
These results suggest that 6-methylquinoline has no tumour-initiating properties in skin, under the
conditions of this study. This would support the lack of carcinogenicity as reported in the study by
Fukushima et al. (1981).
The Panel considered the data on 6-methylquinoline sufﬁcient to disregard the observations with
quinoline and other methylquinolines.
4.4. Application of the procedure
4.4.1. Application of the procedure to 22 pyridine, pyrrole and quinoline
derivatives by JECFA (JECFA, 2005b, 2006a)
According to JECFA, three of the substances belong to structural class I, 13 to structural class II
and six to structural class III, using the decision tree approach presented by Cramer et al. (1978).
JECFA concluded 20 pyridine, pyrrole and quinoline derivatives at step A3 in the JECFA Procedure,
i.e. the substances are expected to be metabolised to innocuous products (step 2) and the intakes for
all substances are below the thresholds for their structural classes I, II and III (step A3).
Two substances, 1-furfurylpyrrole [FL-no: 13.134] and 2-pyridine methanethiol [FL-no: 14.030],
were evaluated via the B-side of the Procedure as the substances could not be anticipated to be
metabolised to innocuous products. For these substances, the intake is below the threshold for the
structural class III (step B3) and a NOAEL exists to provide an adequate margin of safety to the
estimated intake as ﬂavouring substances (step B4). For 1-furfurylpyrrole [FL-no: 13.134], a NOAEL of
12 mg/kg bw per day from a 90-day feeding study in rats (Morgareidge, 1971) is > 1,000,000 times
greater than the estimated current intake of this substance as a ﬂavouring substance. For 2-pyridine
methanethiol [FL-no: 14.030], the NOAEL of 3.4 mg/kg bw per day from a 90-day feeding study in
rats (Posternak et al., 1969) is > 20,000,000 times higher than the estimated current intake of this
substance as a ﬂavouring substance.
In conclusion, JECFA evaluated all 22 substances as to be of no safety concern at the estimated
levels of intake as ﬂavouring substances based on the MSDI approach.
The evaluations of the 22 pyridine, pyrrole and quinoline derivatives are summarised in Appendix C,
Table C.1.
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4.4.2. Application of the procedure to 24 pyridine, pyrrole, indole and quinoline
derivatives from chemical group 28 evaluated by EFSA in FGE.24Rev2
(EFSA CEF Panel, 2013)
Twenty-four candidate substances were evaluated in FGE.24Rev2. Twenty-two of the 24 candidate
substances are classiﬁed into structural class II and two substances into structural class III using the
decision tree approach presented by Cramer et al. (1978).
Two of the substances, ethyl nicotinate [FL-no: 14.110] and isopropyl nicotinate [FL-no: 14.120],
were concluded at step A3, i.e. the substances are expected to be metabolised to innocuous products
(step 2) and the estimated daily intake is below the threshold for the structural class (step A3).
The remaining 22 substances were concluded at step B4, i.e. the substances could not be
anticipated to be metabolised to innocuous products (step 2) and the estimated daily intake is below
the threshold for the structural class (step B3). For the 22 substances, NOAELs could be derived to
provide adequate margins of safety to the estimated levels of intake as ﬂavouring substance (step B4).
For the candidate substance 2-acetyl-5-methylpyrrole [FL-no: 14.085], a NOAEL of 48 mg/kg bw per
day for the supporting substance 2-acetylpyrrole [FL-no: 14.047] is derived. The estimated daily per
capita intake of 0.0012 lg for 2-acetyl-5-methylpyrrole [FL-no: 14.085] corresponds to 0.02 ng/kg bw
per day at a body weight of 60 kg. Thus, a margin of safety of 2.4 9 109 can be calculated. 2-Acetyl-5-
methylpyrrole is accordingly not expected to be of safety concern at the estimated level of intake.
In an oral 37 weeks feeding study in rats on indole-3-carbinole, a substance structurally related to
the two indole derivatives in this FGE (FGE.24Rev2), a NOAEL of 50 mg/kg bw per day could be
derived. The combined estimated daily per capita intake of 0.0024 lg for 1-acetylindole [FL-no:
14.088] and 2-methylindole [FL-no: 14.131] corresponds to 0.04 ng/kg bw per day at a body weight
of 60 kg. Thus, a margin of safety of 1.3 9 109 can be calculated. 1-Acetylindole [FL-no: 14.088] and
2-methylindole [FL-no: 14.131] are accordingly not expected to be of safety concern at the estimated
level of intake.
A 90-day oral feeding study in rats is available for the supporting substance 2-acetylpyridine [FL-no:
14.038]. The NOAEL derived is 37 mg/kg bw per day. The MSDI values for the 19 pyridine derivatives
in this FGE (EFSA CEF Panel, 2013) are between 0.012 and 0.21 lg/capita per day. The combined
estimated daily per capita intake of these 19 derivatives is 1.5 lg, corresponding to 0.025 lg/kg bw
per day. Thus, a margin of safety of 1.5 9 106 can be calculated using the NOAEL of 37 mg/kg bw per
day. The 19 pyridine derivatives in this ﬂavouring group are accordingly not expected to be of safety
concern at the estimated level of intake.
In conclusion, the Panel evaluated the 24 substances as to be of no safety concern at the
estimated levels of intake as ﬂavouring substances based on the MSDI approach.
The stepwise evaluations of the 24 substances are summarised in Appendix C, Table C.2 of the
present opinion.
4.4.3. EFSA consideration
The Panel agrees with the way the application of the Procedure has been applied by JECFA for four
of the 22 substances. Methyl nicotinate [FL-no: 14.071], indole [FL-no: 14.007] and 3-methylindole
[FL-no: 14.004] were evaluated via the A-side of the Procedure as they were anticipated to be
metabolised to innocuous products. For these three substances, EFSA agreed no safety concern at
step A3 of the Procedure, as the intake is below the threshold of the structural class (Cramer et al.,
1978). 1-Furfurylpyrrole [FL-no: 13.134] and 2-pyridine methanethiol [FL-no: 14.030] were the only
two substances evaluated through the B-side of the Procedure as the substances were not anticipated
to be metabolised to innocuous products by JECFA. For 1-furfurylpyrrole [FL-no: 13.134],9 EFSA
disagreed with JECFA, as the 90-day feeding study in rats (Morgareidge, 1971) was considered a
poorly reported old study, the quality of which cannot be assessed, as stated in FGE.24 (EFSA, 2006).
For 2-pyridine methanethiol [FL-no: 14.030], EFSA agrees with JECFA.
For 6-methylquinoline [FL-no: 14.042], contrary to JECFA, the Panel concluded in FGE.77, that this
substance should not be evaluated using the Procedure until adequate in vivo genotoxicity data
become available. Additional genotoxicity data have become available for 6-methylquinoline after the
publication of FGE.77, which have been evaluated in Revision 1 of FGE.77; however, the data were not
sufﬁcient to rule out the concern on the genotoxic potential of 6-methylquinoline. New in vivo
genotoxicity data have been provided for 6-methylquinoline, a Comet assay in duodenum and liver of
9 [FL-no: 13.134] has been removed from FGE.24 Revision 2.
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rats and a combined gene mutation assay and MN assay in MutaTMMice. Based on these studies, the
genotoxicity concern for 6-methylquinoline [FL-no: 14.042] can be ruled out.
The carcinogenicity study in rats on 6-methylquinoline (Fukushima et al., 1981) reports few study
details and only one single dose of 6-methylquinoline was tested. Despite these limitations, this study
suggests that 6-methylquinoline is not carcinogenic in rats under condition of the experiment. It induced
an increase of liver hyperplastic nodules (not statistically signiﬁcant) compared to controls. In addition,
6-methylquinoline did not induce skin tumours in a tumour-initiating test in mice (La Voie et al., 1984).
The only 90-day study in rats on 6-methylquinoline (Posternak et al., 1969) is of very limited
quality, but was acceptable at the time the study was performed; it suggests that at a level around
2 mg/kg bw per day, no changes in a number of parameters measured occurred. If this dose is
considered as a NOAEL, which is supported by the absence of strong indications of toxicity at higher
exposure and longer duration in the study by Fukushima et al. (1981), an adequate margin of safety
of approximately 400,000 can be calculated based on the MSDI.
For the remaining 16 substances, the Panel, in contrast to JECFA, did not anticipate that they will
be metabolised to innocuous products due to concern with respect to N-oxidation of pyridines and for
the pyrroles concerns about N-oxidation and epoxidation and accordingly concluded that they should
be evaluated along the B-side. However, in FGE.77, for 10 [FL-no: 14.038, 14.039, 14.058, 14.059,
14.060, 14.061, 14.065, 14.066, 14.072 and 14.164] of these 16 substance, a NOAEL could be derived
to provide adequate margins of safety to the estimated level of intakes as ﬂavouring substance (step
B4). A 90-day oral-feeding study in rats is available for 2-acetylpyridine [FL-no: 14.039]. The NOAEL
derived is 37 mg/kg bw per day (Til and van der Meulen, 1971). The MSDI values for the 10 pyridine
derivatives in this FGE are between 0.06 and 50 lg/capita per day. The combined estimated daily per
capita intake of the 10 pyridine derivatives evaluated through the B-side is 57 lg corresponding to
0.95 lg/kg bw per day. Thus, a margin of safety of approximately 39,000 can be calculated using the
NOAEL of 37 mg/kg bw per day. The 10 pyridine derivatives in this ﬂavouring group evaluated through
the B-side are accordingly not expected to be of safety concern at the estimated levels of intake.
For pyrrole [FL-no: 14.041] and the ﬁve pyrrole derivatives [FL-no: 13.134, 14.045, 14.046, 14.047
and 14.068] as well as for isoquinoline [FL-no: 14.001], NOAELs could not be derived as such or for
structurally related substances in FGE.77. Accordingly, additional toxicological data were required for
these seven substances (step B4) in FGE.77.
Additional toxicity data have become available, after the publication of FGE.77, for isoquinoline [FL-
no: 14.001], pyrrole [FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047] (Kojima, 2006, Marumo, 2008
and Bauter, 2012b), the latter also to cover the evaluation of the structurally related 2-propionylpyrrole
[FL-no: 14.068].
Based on the data for isoquinoline [FL-no: 14.001] (Kojima, 2006), a NOAEL of 3 mg/kg bw per
day could be established. When comparing this NOAEL at step B4 in the Procedure to the estimated
exposure based on the MSDI (0.012 lg/capita per day, corresponding to 0.0002 lg/kg bw per day),
an adequate margin of safety of 15 9 106 can be calculated.
Based on the data for pyrrole [FL-no: 14.041] (Marumo, 2008), a NOAEL of 3 mg/kg bw per day
could be established. When comparing this NOAEL at step B4 in the Procedure to the estimated
exposure based on the MSDI (0.11 lg/capita per day, corresponding to 0.0018 lg/kg bw per day), an
adequate margin of safety of 16 9 105 can be calculated.
Based on the data for 2-acetylpyrrole [FL-no: 14.047] (Bauter, 2012b), a NOAEL of 48 mg/kg bw
per day could be established. When comparing the NOAEL at step B4 in the Procedure to the
estimated exposure based on the MSDI (3.3 lg/capita per day, corresponding to 0.055 lg/kg bw per
day), an adequate margin of safety of 87 9 104 can be calculated. For 2-propionylpyrrole [FL-no:
14.068], supported by 2-acetylpyrrole [FL-no: 14.047], the MSDI is 0.012 lg/capita per day, which is
well below the MSDI of 2-acetylpyrrole and accordingly not expected to be of safety concern at the
estimated levels of intake.
Additional toxicity data have become available, after the publication of FGE.77Rev1, for 1-
furfurylpyrrole [FL-no: 13.134] (Kappeler, 2013b). The data are intended to cover the re-evaluation of
this substance and 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no:
14.046]. The main study provided is a 90-day study.
Based on the data submitted for 1-furfurylpyrrole [FL-no: 13.134] (Kappeler, 2013b), a NOAEL of
25 mg/kg bw per day could be established. When comparing this NOAEL at step B4 in the Procedure
to the estimated exposure based on the MSDI (0.12 lg/capita per day, corresponding to 0.002 lg/kg
bw per day), an adequate margin of safety of 12.5 9 106 can be calculated. For 2-acetyl-1-
ethylpyrrole [FL-no: 14.045], supported by 1-furfurylpyrrole [FL-no: 13.134], the MSDI is also 0.12 lg/
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capita per day and accordingly not expected to be of safety concern at the estimated levels of intake.
For 2-acetyl-1-methylpyrrole [FL-no: 14.046], the MSDI is 1.2 lg/capita per day which is 10 times the
ﬁgure for the MSDI of 1-furfurylpyrrole resulting in an adequate margin of safety of 12.5 9 105; 2-
acetyl-1-methylpyrrole [FL-no: 14.046] is accordingly not expected to be of safety concern at the
estimated levels of intake.
5. Conclusions
The present Revision of FGE.77, FGE.77Rev3, includes the assessment of additional genotoxicity
data for 6-methylquinoline [FL-no: 14.042]. The studies provided are an in vivo Comet assay in rats
and a combined gene mutation and MN assay in MutaTMMice. The applicant also submitted toxicity data
for 6-methylquinoline.
The Panel concluded that the 22 substances in the JECFA ﬂavouring group of pyridine, pyrrole and
quinoline derivatives are structurally related to the group of pyridine, pyrrole, indole and quinoline
derivatives from chemical group 28 evaluated by EFSA in the Flavouring Group Evaluation 24, Revision
2 (FGE.24Rev2).
JECFA evaluated two substances [FL-no: 13.134 and 14.030] via the B-side of the Procedure and
20 substances via the A-side.
The Panel agrees with the way that the application of the Procedure has been applied by JECFA for
four of the 22 substances. Three of these four substances, methyl nicotinate [FL-no: 14.071], indole
[FL-no: 14.007] and 3-methylindole [FL-no: 14.004], were evaluated by JECFA on the A-side of the
Procedure, as they were anticipated to be metabolised to innocuous products. For these three
substances, the Panel agreed no safety concern at step A3 of the Procedure, as their intake estimates
(MSDI) were below the threshold of their structural class. For the fourth substance, 2-pyridine
methanethiol [FL-no: 14.030], the Panel agreed with JECFA that it should be evaluated through the B-
side of the Procedure, as the substance was not anticipated to be metabolised to innocuous products.
However, a NOAEL was derived from a 90-day study, which provided an adequate margin of safety.
For 1-furfurylpyrrole [FL-no: 13.134], EFSA disagreed with JECFA, as the 90-day feeding study in
rats was considered a poorly reported old study, the quality of which cannot be assessed. However, for
this substance, additional toxicity data were submitted and evaluated in FGE.77Rev2. Based on these
data, adequate margins of safety could be calculated for [FL-no: 13.134, 14.045 and 14.046].
For 16 substances, the Panel, in contrast to JECFA, did not anticipate that they will be metabolised
to innocuous products and accordingly concluded that they should be evaluated along the B-side of
the Procedure. However, in FGE.77, for 10 [FL-no: 14.038, 14.039, 14.058, 14.059, 14.060, 14.061,
14.065, 14.066, 14.072 and 14.164] of these 16 JECFA-evaluated pyridine derivatives evaluated via the
B-side of the Procedure by EFSA, NOAELs could be derived to provide adequate margins of safety and
the Panel agrees with the JECFA conclusion ‘no safety concern at estimated levels of intake as
ﬂavouring substances’ based on the MSDI approach.
In FGE.77Rev1, three 90-day studies were evaluated for isoquinoline [FL-no: 14.001], pyrrole
[FL-no: 14.041] and 2-acetylpyrrole [FL-no: 14.047] and NOAELs to provide adequate margin of safety
were derived to cover these three substances as well as the structurally related 2-propionylpyrrole
[FL-no: 14.068].
In FGE.77Rev2, one 90-day study was evaluated for 1-furfurylpyrrole [FL-no: 13.134]. A NOAEL to
provide adequate margin of safety was derived to cover this substance as well as the structurally
related 2-acetyl-1-ethylpyrrole [FL-no: 14.045] and 2-acetyl-1-methylpyrrole [FL-no: 14.046].
In previous revisions of this FGE, the Panel concluded, contrary to JECFA, that 6-methylquinoline
[FL-no: 14.042] (evaluated via the A-side by JECFA) should not be evaluated through the Procedure
due to concern with respect to genotoxicity in vitro.
Based on the available data and the new in vivo genotoxicity studies on 6-methylquinoline [FL-no:
14.042], the Panel concluded that, for 6-methylquinoline [FL-no: 14.042], there is no concern with respect
to genotoxicity. Therefore, 6-methylquinoline [FL-no: 14.042] can now be evaluated through the Procedure.
The carcinogenicity study in rats on 6-methylquinoline (Fukushima et al., 1981) reports few study
details and only one single dose (0.05% in diet which is equivalent to 25 mg/kg bw per day) of
6-methylquinoline was tested. Despite these limitations, this study suggests that 6-methylquinoline is
not carcinogenic in rats under the condition of the experiment. In addition, 6-methylquinoline did not
induce skin tumours in a tumour-initiating test in mice (La Voie et al., 1984).
The only 90-day study in rats on 6-methylquinoline (Posternak et al., 1969) is of very limited quality,
but was acceptable at the time the study was performed; it suggests that at a level around 2 mg/kg bw
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per day, no changes in a number of parameters measured occurred. If this dose is considered as a
NOAEL, an adequate margin of safety of approximately 400,000 can be calculated based on the MSDI.
From the group of 22 substances evaluated by JECFA, the Panel evaluated three substances via the
A-side [FL-no: 14.004, 14.007, 14.071] and 19 substances via the B side: [FL-no: 13.134, 14.001,
14.030, 14.038, 14.039, 14.041, 14.042, 14.045, 14.046, 14.047, 14.058, 14.059, 14.060, 14.061,
14.065, 14.066, 14.068, 14.072 and 14.164]. For these 19 substances, NOAELs could be derived,
which provided adequate margins of safety.
For the following substances [FL-no: 13.134, 14.001, 14.030, 14.041, 14.042, 14.058, 14.072], the
Industry has submitted use levels for normal and maximum use. For the remaining 15 substances, use
levels are needed to calculate the mTAMDIs in order to identify those ﬂavouring substances that need
more reﬁned exposure assessment and to ﬁnalise the evaluation.
In order to determine whether the conclusion for the 22 JECFA evaluated substances can be
applied to the materials of commerce, it is necessary to consider the available speciﬁcations. Adequate
speciﬁcations including complete purity criteria and identity tests are available for the 22 JECFA-
evaluated substances.
Thus, for the 22 JECFA evaluated pyridine, pyrrole and quinoline derivatives [FL-no: 13.134, 14.001,
14.004, 14.007, 14.030, 14.038, 14.039, 14.041, 14.042, 14.045, 14.046, 14.047, 14.058, 14.059, 14.060,
14.061, 14.065, 14.066, 14.068, 14.071, 14.072 and 14.164], the Panel agrees with the JECFA conclusion
‘no safety concern at estimated levels of intake as ﬂavouring substances’ based on the MSDI approach.
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CAS Chemical Abstract Service
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FLAVIS (FL) Flavour Information System (database)
GLP Good Laboratory Practise
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i.p. Intraperitoneal
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JECFA The Joint FAO/WHO Expert Committee on Food Additives
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MSDI Maximised Survey-derived Daily Intake
mTAMDI Modiﬁed Theoretical Added Maximum Daily Intake
NCE Normochromatic erythrocyte
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NOAEL No observed adverse effect level
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pfu plaque-forming units
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Appendix A – Summary of genotoxicity data
Table A.1: Genotoxicity data (in vitro/in vivo) JECFA (JECFA, 2006a)
FL-no
JECFA-no
EU Register name
JECFA name
Structural
formula
End-point Test system Concentration Results Reference
In vitro
14.007
1301
Indole HN Reverse mutation S. Typhimurium TA100 ≤ 20 lg/plate Negative(a) Ochiai et al. (1986)
Reverse mutation S. Typhimurium TM677 4 mmol/L
(469 lg/mL)(b)
Negative(c) Kaden et al. (1979)
Reverse mutation S. Typhimurium TA98,
TA100, TA1535, TA1538
4–2,500 lg/plate Negative(d) Anderson and
Styles (1978)
Reverse mutation S. Typhimurium TA98,
TA100
≤ 500 nmol/plate
(59 lg/plate)(b)
Negative(a) Vance et al. (1986)
Reverse mutation S. Typhimurium TA100,
TA1535, TA1537
3 lmol/plate
(351 lg/plate)(b)
Negative(d) Florin et al. (1980)
Reverse mutation S. Typhimurium TA98 0.03–30 lmol/plate
(3.5–3515 lg/plate)(b,e)
Negative(d) Florin et al. (1980)
Reverse mutation S. Typhimurium TA97,
TA102
10–1,000 lg/plate Negative(d) Fujita et al. (1994)
Reverse mutation S. Typhimurium TA98,
TA100
≤ 0.4 lmol/plate
(47 lg/plate)(b)
Negative(d) Sasagawa and
Matsushima (1991)
Mutation E. coli WP2 uvrA/pKM101 ≤ 0.4 lmol/plate
(47 lg/plate)(b)
Negative(d) Sasagawa and
Matsushima (1991)
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FL-no
JECFA-no
EU Register name
JECFA name
Structural
formula
End-point Test system Concentration Results Reference
14.042
1302
6-Methylquinoline N Reverse mutation S. Typhimurium TA100 100–600 lg/plate Positive(c) Dong et al. (1978)
Reverse mutation S. Typhimurium TA98,
TA100 TA1535, TA1537 and
TA1538
≤ 3,600 lg/plate Negative(a),
Positive(c,f)
Wild et al. (1983)
Reverse mutation S. Typhimurium TA98 and
TA100
≤ 6 lmol/plate
(859 lg/plate)(g)
Negative(a)
Positive(c)
Nagao et al. (1977)
Reverse mutation S. Typhimurium TA98 and
TA100
≤ 1,000 lg/plate Negative(a)
Positive(c)
Zeiger et al. (1992)
Reverse mutation S. Typhimurium TA98 and
TA100
NR Negative(a)
Positive(c)
Sugimura et al. (1976)
Reverse mutation S. Typhimurium TA100 5 lmol/plate
(716 lg/plate)(g)
Positive(c) Takahashi et al. (1988)
Reverse mutation S. Typhimurium TA98 NR Negative(d) Debnath et al. (1992)
Reverse mutation S. Typhimurium TA100 3.3–333 lg/plate Negative(a)
Positive(c)
Debnath et al. (1992)
14.001
1303
Isoquinoline N Reverse mutation S. Typhimurium TA98 and
TA100
20–50 lg/mL Negative(d) Sideropoulos and Specht
(1984)
Reverse mutation S. Typhimurium TM677 ≤ 8 mmol/L
(1,033 lg/mL)(h)
Negative(c) Kaden et al. (1979)
Reverse mutation S. Typhimurium TA98 and
TA100
NR Negative(d) Sugimura et al. (1976)
Reverse mutation S. Typhimurium TA98 and
TA100
1–20 lmol/plate
(129–2,583 lg/plate)(h)
Negative(d) Nagao et al. (1977)
Reverse mutation S. Typhimurium TA98 and
TA100
10,000–20,000 lg/mL Negative(d) Epler et al. (1979)
Mutation E. coli B/r HCR+ 50 lg/mL Negative(d) Sideropoulos and Specht
(1984)
Unscheduled DNA
synthesis
Rat hepatocytes NR Negative Williams (1984)
N
Flavouring group evaluation 77 revision 3
www.efsa.europa.eu/efsajournal 32 EFSA Journal 2018;16(4):5226
FL-no
JECFA-no
EU Register name
JECFA name
Structural
formula
End-point Test system Concentration Results Reference
14.004
1304
3-Methylindole HN Reverse mutation S. Typhimurium TA100,
TA1535 and TA1537
3 lmol/plate
(394 lg/plate)(i)
Negative(d) Florin et al. (1980)
Reverse mutation S. Typhimurium TA98 0.03–30 lmol/plate
(3.9–3,935 lg/plate)(i)
Negative(d,j) Florin et al. (1980)
Reverse mutation S. Typhimurium TA98 and
TA100
NR Negative(c) Kim et al. (1989)
Reverse mutation S. Typhimurium TA98 and
TA100
≤ 0.4 lmol/plate
(52 lg/plate)(i)
Negative(d) Sasagawa and
Matsushima (1991)
Reverse mutation S. Typhimurium TA100 ≤ 100 lg/plate Negative(a) Ochiai et al. (1986)
Mutation E. coli WP2 uvrA/pKM101 ≤ 0.4 lmol/plate
(52 lg/plate)(i)
Negative(d) Sasagawa and
Matsushima (1991)
Mutation E. coli Sd-4-73 0.01–0.025 mL/disk Negative Szybalski (1958)
DNA single-strand
break
Bovine kidney cells 10 lmol–1 mmol/L
(1.31–131.18 lg/mL)(i)
Positive Kim et al. (1989)
14.047
1307
2-Acetylpyrrole HN
O
Reverse mutation S. Typhimurium TA98 and
TA100
12.5–200 lg/plate Negative(d) Wang et al. (1994)
Reverse mutation S. Typhimurium TA98 4–100 lmol/plate
(437–10,913 lg/plate)(k)
Negative(c)
Positive(a)
Lee et al. (1994)
Reverse mutation S. Typhimurium TA100 4–100 lmol/plate
(437–10,913lg/plate)(k)
Negative(d) Lee et al. (1994)
14.038
1309
2-Acetylpyridine
N
O Mitotic aneuploidy S. cerevisiae D61.M 0.50–0.87%
(54,000–939,600 lg/mL)(l)
Positive Zimmermann et al.
(1986)
14.041
1314
Pyrrole HN Reverse mutation S. Typhimurium TA98,
TA100 and TA102
14 nmol/plate
1.4 mmol/plate
(0.94–93,926 lg/plate)(m)
Negative(d) Aeschbacher et al.
(1989)
Reverse mutation S. Typhimurium TA100,
TA1535 and TA1537
3 lmol/plate
(201 lg/plate)(l)
Negative(d) Florin et al. (1980)
Reverse mutation S. Typhimurium TA98 0.03–30 lmol/plate
(2.01–2013 lg/plate)(m)
Negative(d) Florin et al. (1980)
Reverse mutation S. Typhimurium TA98 and
TA100
NR Negative(d) Lee et al. (1994)
Unscheduled DNA
synthesis
Rat hepatocytes NR Negative Williams (1984)
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FL-no
JECFA-no
EU Register name
JECFA name
Structural
formula
End-point Test system Concentration Results Reference
14.061
1315
3-Ethylpyridine N Reverse mutation S. Typhimurium TA98,
TA100, TA1535 and TA1537
3 lmol/plate
(321 lg/plate)(n)
Negative(d) Florin et al. (1980)
14.039
1316
3-Acetylpyridine
N
O
Mutation E. coli WP2 uvrA 5,000–10,000 lg/plate Negative Pai et al. (1978)
Mitotic aneuploidy S. cerevisiae D61.M 0.5–1.11%
(55,100–122,322 lg/mL)(o)
Positive Zimmermann et al.
(1986)
In vivo
14.042
1302
6-Methylquinoline
N
Sex-linked recessive
mutation
Drosophila melanogaster 10 mmol/L (1432 lg/mL)(g) Negative Wild et al. (1983)
Micronucleus
formation
NMRI mouse 0, 286, 429 or 572 mg/kg
bw
Negative Wild et al. (1983)
NR: Not reported.
(a): Without metabolic activation.
(b): Calculated based on relative molecular mass = 117.15.
(c): With metabolic activation.
(d): With and without metabolic activation.
(e): Toxic at concentrations > 3.0 mmol/plate (351 mg/plate).
(f): TA100 and TA1535.
(g): Calculated based on relative molecular mass = 143.19.
(h): Calculated based on relative molecular mass = 129.16.
(i): Calculated based on relative molecular mass = 131.18.
(j): Toxic at concentrations of > 3.0 mmol/plate (394 mg/plate).
(k): Calculated based on relative molecular mass = 109.13.
(l): Calculated based on density = 1.08 g/mL (Sigma-Aldrich, 2003; available at http://www.sigmaaldrich.com).
(m): Calculated based on relative molecular mass = 67.09.
(n): Calculated based on relative molecular mass = 107.16.
(o): Calculated based on density = 1.102 g/mL (Sigma-Aldrich, 2003; available at http://www.sigmaaldrich.com).
Flavouring group evaluation 77 revision 3
www.efsa.europa.eu/efsajournal 34 EFSA Journal 2018;16(4):5226
Table A.2: Genotoxicity data (in vitro) EFSA/FGE.24Rev2 (EFSA CEF Panel, 2013)
Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
(Pyrrole [14.041]) Ames assay
(modiﬁed
preincubation
method)
S. Typhimurium
TA98; TA100; TA102
1.4 mmol/plate
(93,926 lg/plate)
Negative(a) Aeschbacher et al. (1989)
Ames assay
(preincubation
method)
S. Typhimurium
TA100; TA1535; TA1537
3 lmol/plate
(201 lg/plate)
Negative(a) Florin et al. (1980)
Ames assay
(preincubation
method)
S. Typhimurium
TA98
30 lmol/plate
(2013 lg/plate)
Negative(a)
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98; TA100
Not reported Negative(c) Lee et al. (1994)
Rec assay B. subtilis
H17 (rec+), M45 (rec)
4 and 20 mg/disk Positive(c) Kim et al. (1987) Poor predictive value for
mutagenicity. Limited value
Unscheduled DNA
synthesis
Rat hepatocytes Not reported Negative Williams (1984)
1-Methylpyrrole Ames assay
(modiﬁed
preincubation
method)
S. Typhimurium
TA98; TA100; TA102
11 nmol–1.1 mmol/plate Negative(a) Aeschbacher et al. (1989) 6 dose levels. The study is
considered valid
Rec assay B. subtilis H17 (rec+)
M45 (rec)
2, 4, 20 and 40 mg/disk
(500.5 lmol/disk)
Positive(a) Kim et al. (1987) Poor predictive value for
mutagenicity. Limited value
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Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
(Indole [14.007]) Ames assay
(preincubation
method)
S. Typhimurium
TA100
20 lg/plate Negative(b) Ochiai et al. (1986)
Ames assay S. Typhimurium
TM677
4 mM
(469 lg/mL)
Negative(c) Kaden et al. (1979)
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1538
2,500 lg/plate Negative(a) Anderson and Styles,
(1978)
Ames assay S. Typhimurium
TA98; TA100
500 nmol/plate
(59 lg/plate)
Negative(b) Vance et al. (1986)
Ames assay
(preincubation
method)
S. Typhimurium
TA100; TA1535; TA1537
3 lmol/plate
(351 lg/plate)
Negative(a) Florin et al. (1980)
S. Typhimurium
TA98
30 lmol/plate
(3,515 lg/plate)
Negative(c)
S. Typhimurium
TA97; TA102
1,000 lg/plate Negative(a) Fujita et al. (1994)
S. Typhimurium TA98;
TA100
E. coli WP2uvrA/pKM101
0.4 lmol/plate
(47 lg/plate)
Negative(a) Sasagawa and Matsushima
(1991)
S. Typhimurium
TA100
500 lg/plate Negative(b) Hashizume et al. (1991)
2-Methylindole
[14.131]
Ames assay
(preincubation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1538
4, 20, 100, 500 and
2,500 lg/plate
Negative(a) Anderson and Styles
(1978)
The study is considered valid
S. Typhimurium
TA98; TA100; TA1535;
TA1537
3 lmol/plate
(394 lg/plate)
Negative(a) Florin et al. (1980) Single-dose study
Ames assay S. Typhimurium
TA98
3 nmol–30 lmol/plate
(12 doses)
(3,935 lg/plate)
Negative(a) Curvall et al. (1982) The study is considered valid.
S. Typhimurium
TM677
2 mM
(262 lg/mL)
Negative Kaden et al. (1979) Single-dose study.
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Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
(3-Methylindole
[14.004])
Ames assay
(preincubation
method)
S. Typhimurium
TA100; TA1535; TA1537
3 lmol/plate
(394 lg/plate)
Negative(a) Florin et al. (1980)
S. Typhimurium
TA98
30 lmol/plate
(3,935 lg/plate)
Negative(a)
Ames assay S. Typhimurium
TA98; TA100
Not reported Negative(c) Kim et al. (1989)
Ames assay
(preincubation
method)
S. Typhimurium TA98;
TA100
E. coli WP2uvrA/pKM101
0.4 lmol/plate
(52 lg/plate)
Negative(a) Sasagawa and Matsushima
(1991)
S. Typhimurium
TA100
100 lg/plate Negative(b) Ochiai et al. (1986)
S. Typhimurium
TA100
Up to 3.33 mM
(437 lg/mL)
Negative(c) Reddy et al. (2002)
Mutation assay
(paper-disk method)
E. coli
Sd-4-73
0.025 mL/disk Negative Szybalski (1958)
Chromosomal
aberration assay
Chinese hamster ovary
cells
1.3, 1.4 and 1.5 mM
(+ S9)
1.4, 1.5 and 1.6 mM
( S9)
Positive(a) Reddy et al. (2002) Aberrations were only detected
at cytotoxic concentrations that
showed marked inhibition of DNA
synthesis
Alkaline elution assay Rat primary hepatocytes
(uninduced and PB/b-NF
induced)
0.5, 0.6, 0.7, 0.8, 0.9
and 1 mM
Negative Reddy et al. (2002) The study is considered valid
DNA modiﬁcation
assay
Isolated human genomic
DNA
25 and 500 lM
(66 lg/mL)
Positive(c)
Negative(b)
Laws et al. (2001) Assay demonstrating inhibition of
PCR ampliﬁcation and spots
demonstrated by postlabeling.
Limited predictive value
DNA Single-strand
break assay
Bovine kidney cells 10 lM–1 mM
(131.2 lg/mL)
Positive Kim et al. (1989) Abstract only. Validity cannot be
evaluated
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Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
(2-Acetylpyrrole
[14.047])
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98
4, 20 and 100 lmol/plate
(10913 lg/plate)
Negative(c)
Positive(b)
Lee et al. (1994) Positive without S9 only at the
two highest concentrations. High
concentrations. Technically
acceptable, but of limited
relevance due to high
concentrations.
S. Typhimurium
TA100
100 lmol/plate
(10,913 lg/plate)
Negative(a)
Ames assay S. Typhimurium
TA98; TA100
Up to 200 lg/plate Negative(a) Wang et al. (1994)
2-Methylpyridine
[14.134]
Ames assay
(preincubation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537
3 lmol/plate
(279 lg/plate)
Negative(a) Florin et al. (1980) Single-dose study
Ames assay
(modiﬁed
preincubation
method)
S. Typhimurium
TA98; TA100; TA102
10 nmol–1 mmol/plate
(6 doses)
(93 lg/mL)
Negative(a) Aeschbacher et al. (1989) The study is considered valid
Ames assay
(plate incorporation
method)
S. Typhimurium
TA97; TA98; TA100;
TA102
Up to 5,000 lg/plate
(6 doses)
Negative(a) Claxton et al. (1987) Individual dose levels not
reported. The study is
considered valid
S. Typhimurium
TA98; TA100; TA1535;
TA1537
50, 160, 500, 1,600 and
5,000 nL/plate
(4,722 lg/plate)
Negative(a) Vleminckx et al. (1993a) The study is considered valid
Mitotic aneuploidy
assay
S. cerevisiae
D61.M
0.5–0.74%
(6 doses)
(6988 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance
HGPRT Gene
mutation assay
Chinese hamster V79
lung cells
4.5, 4.75, 5, 5.25 and
5.5 ll/mL
(5,194 lg/mL)
Negative(b) Vleminckx et al. (1993b) The study is considered valid
Alkaline elution assay Chinese hamster V79
lung cells
2, 3, 4, 5 and 6 lL/mL
(5,666 lg/mL)
Negative(b) Schriewer et al. (1993) The study is considered valid
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Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
3-Methylpyridine
[14.135]
Ames assay
(modiﬁed
preincubation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537
85, 280, 840 and
8,540 lg/plate
Negative Haworth et al. (1983) The study is considered valid
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537
50, 160, 500, 1,600 and
5,000 nL/plate
(4,785 lg/plate)
Negative(a) Vleminckx et al. (1993a) The study is considered valid
Mutagenicity assay E. coli
WP2 uvrA
5–10 mg/plate
(5000–10,000 lg/plate)
Negative Pai et al. (1978) Single-dose study. Very few
experimental details. The validity
cannot be evaluated
HGPRT Gene
mutation assay
Chinese hamster
V79 lung cells
3, 3.25, 3.5, 3.75 and
4 lL/mL
(3,828 lg/mL)
Negative(b) Vleminckx et al. (1993b) The study is considered valid
Alkaline elution assay Chinese hamster
V79 lung cells
2, 3, 4 and 5 lL/mL
(4,785 lg/mL)
Negative(b) Schriewer et al. (1993) The study is considered valid.
4-Methylpyridine
[14.136]
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537
50, 160, 500, 1,600 and
5,000 nL/plate
(4779 lg/plate)
Negative(a) Vleminckx et al. (1993a) The study is considered valid.
HGPRT Gene
mutation assay
Chinese hamster
V79 lung cells
3.75, 4, 4.25 and
4.5 lL/mL
(4,301 lg/mL)
Negative(b) Vleminckx et al. (1993b) The study is considered valid.
Alkaline elution assay Chinese hamster
V79 lung cells
3.75, 4, 4.25 and
4.5 lL/mL
(4,301 lg/mL)
Negative(b) Schriewer et al. (1993) The study is considered valid.
(3-Ethylpyridine
[14.061])
Ames assay
(preincubation
method)
S. Typhimurium TA98;
TA100; TA1535; TA1537
3 lmol/plate
(321 lg/plate)
Negative(a) Florin et al. (1980) Single-dose study.
2,4-
Dimethylpyridine
[14.104]
Mitotic aneuploidy
assay
S. cerevisiae D61.M 0.4–0.60%
(6 doses)
(5,551 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance
(2,6-
Dimethylpyridine
[14.065])
Mitotic
aneuploidy assay
S. cerevisiae
D61.M
0.5–0.60%
(4 doses)
(5,551 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance.
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Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
3,5-
Dimethylpyridine
[14.106]
Ames assay
(preincubation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537
3 lmol/plate
(321 lg/plate)
Negative(a) Florin et al. (1980) Single-dose study
(2-Acetylpyridine
[14.038])
Ames assay
(plate incorporation
method)
S. Typhimurium
TA98; TA100; TA1535;
TA1537; TA1538
100–10,000 lg/plate Negative Longfellow (1997) Very short summary. The results
cannot be validated. High doses.
Mouse lymphoma
assay
Mouse lymphocytes
L5178Y tk+/–
2,500–4,500 lg/mL
( S9)
1,000–4,000 lg/mL
(+ S9)
Positive(a) Very short summary. The results
cannot be validated
Mitotic aneuploidy
assay
S. cerevisiae
D61.M
0.5–0.87%
(4 doses)
(9,396 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance
(3-Acetylpyridine
[14.039])
Mutation E. coli
WP2uvrA
10,000 lg/plate Negative Pai et al. (1978) Single-dose study. Very few
experimental details. The validity
cannot be evaluated
Mitotic aneuploidy
assay
S. cerevisiae
D61.M
0.5–1.11%
(5 doses)
(1,223 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance
4-Acetylpyridine
[14.089]
Ames assay
(preincubation
method)
S. Typhimurium
TA97; TA98; TA100;
TA102; TA104; TA1535;
TA1537; TA1538
5, 100, 300, 100, 3,000
and 10,000 lg/plate
Negative(a) Zeiger et al. (1992) The study is considered valid
Mitotic aneuploidy
assay
S. cerevisiae
D61.M
0.5–1.19%
(5 doses)
(13,114 lg/mL)
Positive Zimmermann et al. (1986) Very high doses. The effect is
considered thresholded. Limited
relevance
Mitotic aneuploidy
assay
S. cerevisiae
D61.M
Up to 11 mg/mL Positive Whittaker et al. (1989) Purity 88%. Very high doses.
The effect is considered
thresholded. Limited relevance
*: Supporting substances are listed in brackets.
(a): With and without metabolic activation.
(b): Without metabolic activation.
(c): With metabolic activation.
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Table A.3: Genotoxicity data (in vivo) EFSA/FGE.24Rev2 (EFSA CEF Panel, 2013)
Chemical Name [FL-no]* Test System Test Object Route Dose Result Reference Comments
(3-Methylindole [14.004])* Micronucleus test Mouse Oral 1,000 mg/kg day Negative (Reddy et al. (2003) Abstract only. The validity
cannot be evaluated
*: Supporting substance.
Table A.4: Genotoxicity data (in vitro) on 6-Methylquinoline
Chemical Name
[FL-no]
Test System Test Object Concentration Result Reference Comments
6-Methylquinoline
[14.042]
Chromosomal aberration assay Chinese hamster
ovary cells
52.7, 69.9, 174.8 and 349.5 lg/mL
50.3, 125.5, 250.9 and 374.5 lg/mL
Negative ( S9)
Positive (+ S9)
NTP (1986)
Sister chromatid exchanges Chinese hamster
ovary cells
16.6, 25.1, 33 and 50 lg/mL
16.7, 50.1, 166.9 and 500.7 lg/mL
Positive ( S9)
Positive (+ S9)
NTP (1986)
Bacterial reverse mutation assay S. Typhimurium
TA98 and TA100
3, 10, 33, 100, 166, 333, 666,
1,000 lg/plate
Negative ( S9)
Positive (+ S9)
NTP (1986)
Table A.5: Genotoxicity data (in vivo) on 6-Methylquinoline and 6-Isopropylquinoline
Chemical Name
[FL-no]
Test System Test Object Route Dose Result Reference Comments
6-Methylquinoline
[14.042]
Micronucleus test Male mice Gavage 0, 225, 450 and
900 mg/kg bw
Negative Nakajima (2005) Limited relevance.
Micronucleus test NMRI mice i.p. 0, 286, 429, or
572 mg/kg bw
Negative Wild et al. (1983) Single intraperitoneal
administration. Limited relevance
Comet assay in liver
and duodenum
Male rat Gavage 100, 200 and
400 mg/kg bw
Equivocal in liver and
Negative in duodenum
Keig-Shevlin (2016) The study complies with OECD test
guideline 489 and GLP guidelines
Gene mutation in
liver and duodenum
Male Muta(™)
mice
Gavage 125, 250,
500 mg/kg bw
per day
Negative Ballantyne (2017) The study complies with OECD test
guideline 488 and GLP guidelines
Micronucleus in
peripheral blood
reticulocytes
Male Muta(™)
mice
Gavage 125, 250,
500 mg/kg bw
per day
Negative
6-Isopropylquinoline Micronucleus test NMRI mice Oral 0, 500, 1,000
and 2,000
mg/kg bw
Negative Honarvar (2004) Limited relevance
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Appendix B – Summary of toxicity data
Table B.1: Toxicity data considered by the panel
Chemical Name
[FL-no]
Species;
Sex
No/group
Route
Doses
(mg/kg bw per day)
Duration
(days)
NOAEL
(mg/kg
bw per
day)
Reference Comments
Isoquinoline
[FL-no: 14.001]
Rat;
M, F
10
Oral 0, 0.03, 0.3 and 3 90 3 Kojima (2006) It is a GLP study performed according to the
Japanese ‘Guidelines for designation of food
additives and revision of standards for use of
food additives, Notiﬁcation No 29’ of the
Environmental Health Bureau, Ministry of
Health and Welfare, Japan, 22 March 1996.
The requirements of this guideline are very
similar to the OECD Guideline 408
Pyrrole
[FL-no: 14.041]
Rat; M, F
10
Gavage 0, 0.03, 0.3 and 3 90 3 Marumo (2008) Same as above
2-Acetylpyrrole
[FL-no: 14.047]
Rat; M, F
3
Diet 0, 85, 550 and 842 (males)
0, 91, 582 and 949 (females)
14 Range
ﬁnding
Bauter (2012a)
Rat; M, F
10
Diet 0, 68, 133 and 263 (males)
0, 79, 155 and 298 (females)
90 48 Bauter (2012b) Compliant to the OECD test guideline 408
1-Furfurylpyrrole
[FL-no: 13.134]
Rat; M, F
3
Diet 0, 29, 84 and 211 (males)
0, 27, 81 and 192 (females)
14 Range-
ﬁnding
Kappeler (2013a)
Rat; M, F
10
Diet 0, 25, 77 and 154 (males)
0, 25, 75 and 151 (females)
90 25 Kappeler (2013b) Compliant to the OECD test guideline 408
6-methylquinoline
[FL-no: 14.042]
Rat; M,F
10 to 16
Diet 2.2 (males) 2.7 (females) 90 2.2 Posternak et al.
(1969)
The study was performed with a single dose
that produced no adverse effects. The report is
only a summary of the study. Poor study
protocol
Rat; M 38,
F 37
Diet 25 mg/kg bw per day 2-year Fukushima et al.
(1981)
Carcinogenicity study. Only one dose was
tested
Mouse; F 30 Skin painting 7.5 mg per animal 18 weeks La Voie et al.
(1984)
Assay for tumour-initiating activity
M: Male.
F: Female.
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Appendix C – Summary of safety evaluations
Table C.1: Summary of Safety Evaluation by JECFA (JECFA, 2005b)
FL-no
JECFA-no
EU Register name
Structural
formula
EU MSDI(a)
US MSDI
(lg/capita
per day)
Class(b)
Evaluation
procedure
path(c)
Outcome on
the named
compound
[(d) or (e)]
EFSA conclusion on the
named compound
(Procedure steps, intake
estimates, NOAEL,
genotoxicity)
EFSA conclusion on the
material of commerce
14.004
1304
3-Methylindole HN 2.4
0.07
Class I
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.007
1301
Indole
H
N 26
10
Class I
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.041
1314
Pyrrole HN 0.11
0.01
Class I
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.038
1309
2-Acetylpyridine
N
O 50
68
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.039
1316
3-Acetylpyridine
N
O
23
0.8
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.045
1305
2-Acetyl-1-ethylpyrrole
N
O
0.12
0.009
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.046
1306
2-Acetyl-1-methylpyrrole
N
O 1.2
0.02
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.047
1307
2-Acetylpyrrole HN
O
3.3
0.2
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.059
1312
3-Isobutylpyridine N 0.049
0.07
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
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FL-no
JECFA-no
EU Register name
Structural
formula
EU MSDI(a)
US MSDI
(lg/capita
per day)
Class(b)
Evaluation
procedure
path(c)
Outcome on
the named
compound
[(d) or (e)]
EFSA conclusion on the
named compound
(Procedure steps, intake
estimates, NOAEL,
genotoxicity)
EFSA conclusion on the
material of commerce
14.060
1313
2-Pentylpyridine
N
0.061
0.07
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.061
1315
3-Ethylpyridine N 9.3
3
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.065
1317
2,6-Dimethylpyridine N 0.26
0.007
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.066
1318
5-Ethyl-2-methylpyridine N 0.12
0.04
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.068
1319
2-Propionylpyrrole HN
O 0.012
2
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.071
1320
Methyl nicotinate
N
O
O
0.49
0.2
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.164
1322
2-Propylpyridine N 0.61
0.9
Class II
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.001
1303
Isoquinoline N 0.012
0.07
Class III
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.042
1302
6-Methylquinoline N 0.32
0.01
Class III
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.058
1311
2-Isobutylpyridine N 0.0061
0.9
Class III
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
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FL-no
JECFA-no
EU Register name
Structural
formula
EU MSDI(a)
US MSDI
(lg/capita
per day)
Class(b)
Evaluation
procedure
path(c)
Outcome on
the named
compound
[(d) or (e)]
EFSA conclusion on the
named compound
(Procedure steps, intake
estimates, NOAEL,
genotoxicity)
EFSA conclusion on the
material of commerce
14.072
1321
2-(3-Phenylpropyl)
pyridine
N 1.8
0.7
Class III
A3: Intake
below threshold
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
13.134
1310
1-Furfurylpyrrole N
O 0.12
0.07
Class III
B3: Intake
below
threshold, B4:
Adequate
NOAEL exists
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
14.030
1308
2-Pyridine methanethiol SH
N
0.0012
0.007
Class III
B3: Intake
below
threshold,
B4: Adequate
NOAEL exists
d No safety concern at the
estimated level of intake
based on the MSDI approach
No safety concern at the
estimated level of intake
based on the MSDI approach
(a): EU MSDI: Amount added to food as ﬂavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day. EU MSDIs may deviate from those reported in
the JECFA evaluation because for several substances new data were available.
(b): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
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Table C.2: Summary of safety evaluation by the EFSA (FGE.24Rev2) (EFSA CEF Panel, 2013)
FL-no EU Register name
Structural
formula
MSDI(a)
(lg/capita
per day)
Class(b)
Evaluation procedure
path(c)
Outcome on the
named compound
[(d) or(e)]
Outcome on the
material of
commerce
[(f), (g), or (h)]
Evaluation
remarks
14.110 Ethyl nicotinate N
O
O
0.013 Class II
A3: Intake below threshold
d f
14.120 Isopropyl nicotinate
N
O
O
0.0012 Class II
A3: Intake below threshold
d f
14.023 1-Methylpyrrole
N
0.3 Class II
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
i
14.085 2-Acetyl-5-methylpyrrole H
N
O 0.0012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.089 4-Acetylpyridine N
O
0.0073 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.092 2-Butylpyridine N 0.012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.093 3-Butylpyridine N 0.061 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.103 2,3-Dimethylpyridine N 0.037 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.104
2151
2,4-Dimethylpyridine N 0.024 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.105 3,4-Dimethylpyridine
N
0.13 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
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FL-no EU Register name
Structural
formula
MSDI(a)
(lg/capita
per day)
Class(b)
Evaluation procedure
path(c)
Outcome on the
named compound
[(d) or(e)]
Outcome on the
material of
commerce
[(f), (g), or (h)]
Evaluation
remarks
14.106 3,5-Dimethylpyridine N 0.073 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.107 2,5-Dimethylpyrrole
H
N 0.061 Class II
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
i
14.115 2-Ethylpyridine N 0.027 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.116 4-Ethylpyridine
N
0.027 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.117 2-Hexylpyridine N 0.012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.118 2-Hydroxypyridine N OH 0.024 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.124 2-Isopropylpyridine
N
0.021 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.125 4-Isopropylpyridine N 0.012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.134 2-Methylpyridine N 0.21 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.135 3-Methylpyridine
N
0.027 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.136 4-Methylpyridine N 0.73 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
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FL-no EU Register name
Structural
formula
MSDI(a)
(lg/capita
per day)
Class(b)
Evaluation procedure
path(c)
Outcome on the
named compound
[(d) or(e)]
Outcome on the
material of
commerce
[(f), (g), or (h)]
Evaluation
remarks
14.140 3-Pentylpyridine N 0.0012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.143 3-Propylpyridine N 0.0012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.145 Pyrrole-2-carbaldehyde HN
O
0.12 Class II
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
j
14.150 2,4,6-Trimethylpyridine N 0.012 Class II
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.169
2150
1-Ethyl-2-
pyrrolecarboxaldehyde N
O
0.12 Class II
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
j
13.100 2-Acetyl-1-furfurylpyrrole
N
O
O
0.091 Class III
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
i
14.088 1-Acetylindole
N
O
0.0012 Class III
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.131 2-Methylindole HN 0.0012 Class III
B3: Intake below threshold,
B4: Adequate NOAEL exists
d f
14.163
2152
1-Methylpyrrole-2-
carboxaldehyde
N
O
0.0024 Class III
B3: Intake below threshold,
B4: No adequate NOAEL
Additional data
required
j
14.002 4-Methylquinoline N 0.12 Class III
No evaluation
i
Flavouring group evaluation 77 revision 3
www.efsa.europa.eu/efsajournal 48 EFSA Journal 2018;16(4):5226
FL-no EU Register name
Structural
formula
MSDI(a)
(lg/capita
per day)
Class(b)
Evaluation procedure
path(c)
Outcome on the
named compound
[(d) or(e)]
Outcome on the
material of
commerce
[(f), (g), or (h)]
Evaluation
remarks
14.094 4-Butylquinoline
N
0.0012 Class III
No evaluation
i
14.138 2-Methylquinoline N 0.012 Class III
No evaluation
i
(a): EU MSDI: Amount added to food as ﬂavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(b): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
(f): No safety concern at the estimated level of intake of the material of commerce meeting the speciﬁcation requirement (based on intake calculated by the MSDI approach).
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or
information on stereoisomerism.
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce.
(i): No longer supported by Industry (DG SANCO, 2012).
(j): No longer supported by Industry (DG SANCO, 2013).
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Appendix D – Exposure data
Table D.1: Normal and Maximum use levels available for substances in FGE.77Rev3
FL-no
Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
13.134 0.011
0.027
0.13
0.27
18
880
29
200
0.037
–
0.00073
0.073
14.001 –
1
0.025
–
0.25
–
0.09
–
14.030 1
–
1
0
1
–
1
–
14.041 3
3
3
3
3
3
3
3
3
3
14.042 0.24
19
2.9 –
9.7
2.9
29
5
–
1.5
13
1.2
–
0.00058
–
14.058 –
1
0.025
–
0.25 0.09
–
14.072 0.2
–
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Table D.2: Estimated intakes based on the MSDI and the mTAMDI(a) approach – FGE.77Rev3
FL-no EU Register name
MSDI – EU
(lg/capita per day)
MSDI – USA
(lg/capita per day)
mTAMDI
(lg/person per day)
Structural class
Threshold of concern
(lg/person per day)
14.004 3-Methylindole 2.4 0.07 Class I 1,800
14.007 Indole 26 10 Class I 1,800
14.041 Pyrrole 0.11 0.01 480 Class I 1,800
14.038 2-Acetylpyridine 50 68 Class II 540
14.039 3-Acetylpyridine 23 0.8 Class II 540
14.045 2-Acetyl-1-ethylpyrrole 0.12 0.009 Class II 540
14.046 2-Acetyl-1-methylpyrrole 1.2 0.02 Class II 540
14.047 2-Acetylpyrrole 3.3 0.2 Class II 540
14.059 3-Isobutylpyridine 0.049 0.07 Class II 540
14.060 2-Pentylpyridine 0.061 0.07 Class II 540
14.061 3-Ethylpyridine 9.3 3 Class II 540
14.065 2,6-Dimethylpyridine 0.26 0.007 Class II 540
14.066 5-Ethyl-2-methylpyridine 0.12 0.04 Class II 540
14.068 2-Propionylpyrrole 0.012 2 Class II 540
14.071 Methyl nicotinate 0.49 0.2 Class II 540
14.164 2-Propylpyridine 0.61 0.9 Class II 540
14.001 Isoquinoline 0.012 0.07 64 Class III 90
14.042 6-Methylquinoline 0.32 0.01 830 Class III 90
14.058 2-Isobutylpyridine 0.0061 0.9 64 Class III 90
14.072 2-(3-Phenylpropyl)pyridine 1.8 0.7 65 Class III 90
13.134 1-Furfurylpyrrole 0.12 0.07 3000 Class III 90
14.030 2-Pyridine methanethiol 0.0012 0.007 520 Class III 90
(a): For the calculation of mTAMDI – see e.g. Annex II in FGE.03 (EFSA, 2004).
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